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Abstract 
Epithelial-mesenchymal transition (EMT) serves as a key mechanism driving 
tumour cell migration, invasion, and metastasis in many carcinomas. Transforming growth 
factor-beta (TGFβ) signalling is implicated in several steps during cancer pathogenesis and 
acts as a classical inducer of EMT. Since epithelial ovarian cancer (EOC) cells have the 
potential to switch between epithelial and mesenchymal states during metastasis, we 
predicted that modulation of TGFβ signalling would significantly impact EMT and the 
malignant potential of EOC spheroid cells. Ovarian cancer patient ascites-derived cells 
naturally underwent an EMT response when aggregating into spheroids, and this was 
reversed upon spheroid re-attachment to a substratum. CDH1/E-cadherin expression was 
markedly reduced in spheroids compared with adherent cells, in concert with an up-
regulation of several transcriptional repressors, i.e., TWIST1/2, ZEB2, and most notably 
SNAI1/Snail.  Treatment of EOC spheroids with the TGFβ type I receptor inhibitor, SB-
431542, severely reduced Snail expression and potently blocked the endogenous activation 
of EMT in spheroids. Furthermore, treatment of spheroids with SB-431542 upon re-
attachment enhanced the epithelial phenotype of dispersing cells and significantly 
decreased cell motility and Transwell migration. Spheroid formation was significantly 
compromised by exposure to SB-431542 that correlated with a reduction in cell viability 
particularly in combination with carboplatin treatment. Thus, our findings are the first to 
demonstrate that intact TGFβ signalling is required to control EMT in EOC ascites-derived 
cell spheroids and it promotes the malignant characteristics of these structures. Next, we 
sought to investigate the function of Snail, the most robustly-upregulated EMT marker in 
EOC spheroids, since its role in EOC metastasis particularly in spheroids is largely 
unknown. Knockdown of SNAI1 encoding Snail led to a modest reduction in spheroid 
formation and cell viability, but we observed a significant decrease in the ability of 
spheroids to migrate due to loss of Snail expression.  Further to this, we retrovirally-
transduced the Hey ovarian cancer cell line to ectopically express Snail.  HeySNAIL cells 
exhibited a strong EMT phenotype in adherent culture, a result which correlated with 
significantly enhanced spheroid cell migration, and adhesion and invasion of spheroids to 
fibronectin and collagen matrices. Furthermore, using an ex ovo chick embryo 
chorioallantoic membrane assay, Snail-expressing EOC spheroids possessed significantly 
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enhanced tumour-forming potential, invasion, and liver metastasis. These results highlight 
the therapeutic potential for targeting the Snail/EMT/TGFβ signalling pathway in patients 
with late-stage ovarian cancer.  
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Chapter 1 
1 INTRODUCTION 
1.1 Overview of Chapter 1 
This thesis focuses on investigating the plasticity of ovarian cancer cells in terms 
of their epithelial and mesenchymal states when they aggregate into 3D formations 
(spheroids) and re-attach onto substratum, and whether this process is dynamically 
regulated by members of the TGFβ/SMAD signalling pathway. Through my investigations, 
we believe to have uncovered important aspects of ovarian cancer spheroid formation and 
metastasis. This chapter begins with a description of ovarian cancer (Section 1.2) 
specifically focusing on the origins, classification, and mortality associated with this very 
complex disease. The next section (Section 1.3) focuses on the spheroid as an in vitro 
model of ovarian cancer metastasis and the unique properties that spheroid cells acquire to 
avoid anoikis and propagate disease. Epithelial-to-mesenchymal transition (EMT) (Section 
1.4) and the transforming growth factor beta (TGFβ) (Section 1.5) signalling pathway will 
be described. Snail/SNAI1, a downstream target of TGFβ signalling and one of the main 
inducers of EMT will also be described (section 1.4.4). The relevance of these topics to 
ovarian cancer will be highlighted, and my data in the following Chapters (2 and 3) will 
show that these pathways are important for the formation, survival, and invasive 
capabilities of ovarian cancer spheroids. The final section of this chapter provides rationale 
for our research (Section 1.6) and outlines the studies presented in this thesis.  
1.2 Ovarian Cancer 
 Classification 
Ovarian cancer may be of germ cell, stromal, or epithelial origin [1]. Epithelial 
ovarian cancer (EOC), the most common type, is the focus of my thesis. Rather than 
existing as a single entity, EOC appears to be a group of distinct diseases that can be further 
classified into the following five histological subtypes: serous, endometrioid, mucinous, 
clear cell, and undifferentiated carcinomas [2]. These tumours morphologically resemble 
various mucosal tissues of the female reproductive tract. For example, serous tumours 
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resemble fallopian tube epithelium, endometrioid tumours resemble endometrial glands, 
and mucinous tumours resemble endocervical glands or gastrointestinal epithelium [3]. 
Among these subtypes, high-grade serous carcinoma (HGSC) is the most prevalent and is 
responsible for the highest fatality rate [4, 5]. 
 A dual classification system of type I and type II tumours has been proposed that 
incorporates genetic profiling of tumours as well as histology and clinical behavior [6, 7]. 
Type I tumours include low-grade serous, endometrioid, mucinous as well as clear cell 
carcinomas, whereas type II carcinomas consist mostly of high-grade serous carcinomas, 
carcinosarcomas and undifferentiated carcinomas [7, 8]. Low-grade carcinomas are slow 
growing and generally more indolent, and often confined to the ovary at diagnosis. In 
contrast, high-grade tumours are clinically aggressive at initial presentation, metastasize 
early, and are associated with poor clinical outcome [9]. Type I tumours usually present 
with mutations in K-ras, B-raf, β-catenin, PI3-kinase pathway and/or PTEN. In contrast, 
Type II tumours display high levels of genomic instability and are characterized mainly by 
TP53 mutations [7, 8]. The Cancer Genome Atlas identified a high frequency (96%) of 
high-grade serous tumours to harbor TP53 mutations. As these genetic alterations occur 
early in the transformation process, the contribution of these genes is suggested to define 
the tumourigenic process as well as histological differentiation. 
 Origins 
It had been long accepted that all EOCs are derived from the ovarian surface 
epithelium (mesothelium) and that subsequent metaplastic changes lead to the development 
of the various cell types that morphologically resemble the epithelium of the female 
reproductive tract [10, 11]. Evidence from the past decade suggests that some human 
HGSCs may originate from secretory epithelial cells of the fallopian tube. Until recently, 
early cancerous or precancerous lesions in the fallopian tubal fimbria (serous tubal 
intraepithelial carcinoma or STIC) had been identified in women harboring the TP53 
mutation as well as BRCA1 or BRCA2 dysfunction in sporadic pelvic serous carcinoma. 
On the basis of these initial studies, and a surge of evidence to follow, the fallopian tube 
has now emerged as an important source for HGSC [12-14].  
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 Treatment and prognosis 
Ovarian cancer is called the ‘silent killer’, since there is no effective diagnostic 
method for detecting these tumours at an early stage and more than 75% of patients have 
advanced disease at initial diagnosis [15]. Around 20% of ovarian cancers are diagnosed 
while they are still limited to the ovaries (stage I). At this stage, up to 90% of patients can 
be cured using currently available therapy. After the disease has metastasized to the pelvic 
organs (stage II), the abdomen (stage III) or beyond the peritoneal cavity (stage VI), the 
cure rate decreases substantially [16]. 
Epithelial ovarian cancer, which constitutes 90% of all ovarian malignancies, is the 
most lethal disease amongst gynecologic malignancies in the western world [17, 18]. 
Because of its absence of obvious symptoms and as mentioned above, lack of effective 
screening tests, the diagnosis of EOC is often made when the disease is at an advanced 
stage, when tumour has spread beyond the ovaries and disseminated into the peritoneal 
cavity, resulting in a survival rate of only 20– 30% [19]. Reasons for this high lethality are 
not only due to the advanced stage at which patients are diagnosed, but also due to the 
inherent aggressive biology of this cancer. Ovarian cancer differs from hematogenously 
spreading tumours in that the cells detach from the primary tumour and disseminate 
throughout the peritoneal cavity, by the flow of peritoneal fluid, to settle onto peritoneal 
surfaces forming numerous nodules. The degree of peritoneal dissemination correlates with 
a worse prognosis in patients with advanced-stage ovarian cancer.  
The standard therapy for advanced ovarian cancer is multidisciplinary treatment 
that combines maximum tumour-debulking surgery with taxane (paclitaxel) and platinum 
(carboplatin) based chemotherapy [20]. Particularly in patients with advanced ovarian 
cancer, it is extremely important to remove as much of the tumour as possible by 
appropriate debulking surgery. However, this is extremely difficult because of diffuse 
tumour spread within the peritoneum. Therefore, almost all patients are treated with 
subsequent chemotherapy to eradicate the residual microscopic and macroscopic peritoneal 
metastases. Initially, ovarian cancer is generally sensitive to anticancer drugs, 
approximately 70% of patients can achieve remission with the standard taxane and 
4 
 
platinum based chemotherapy [21, 22].  Unfortunately, this remission is short lived (lasting 
only 1-2 years after the initiation of treatment) and relapsing tumours are often resistant to 
chemotherapy. Patients inevitably succumb to their disease as a consequence of tumour 
recurrence and metastatic spread [22, 23]. Thus, the long-term prognosis of patients with 
advanced ovarian cancer is very poor. The biological features of tumours and their 
sensitivity to anticancer drugs can also depend on the tumour histology, making matters 
even more complex for treatment [24-26]. Due to the limitations of current standard 
therapy for ovarian cancer, new treatment strategies to improve the long-term prognosis of 
patients with this cancer need to be examined. 
 Metastasis 
The diffuse nature of ovarian cancer metastasis renders treatments increasingly 
ineffective. The intraperitoneal metastasis of ovarian cancer is unique among solid 
tumours, as most of the women with advanced-stage ovarian cancer have diffuse peritoneal 
spread with no clinically apparent hematogenous metastases [27, 28]. Peritoneal 
dissemination is the most frequent route of spread and is the most signiﬁcant prognostic 
factor in ovarian cancer [29]. Ovarian cancer cells commonly shed from the primary 
tumour directly into the peritoneal cavity either as multicellular clusters, or as individual 
tumour cells that can aggregate into multicellular clusters or spheroids (Figure 1.1). This 
is usually associated with a buildup of malignant pertioneal fluid known as ascites, 
particularly in advanced high-grade serous carcinomas. Ascites accumulation occurs 
through the combined effect of lymphatic obstruction by metastatic cancer cells, increased 
production of by mesothelial cells, and increased vascular permeability [30-32]. Spheroids 
free floating in ascites survive and subsequently spread and attach to the peritoneum 
(Figure 1.1) and other intra-abdominal organs including the omentum, diaphragm, and 
small bowel mesentery [33-35]. All of the organs within the peritoneal cavity are lined with 
a continuous monolayer of mesothelial cells [36-38]. Localized proteolytic degradation of 
mesothelial extracellular matrix facilitates the migration of cancer cells allowing them to  
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Figure 1.1: Mechanism of high-grade serous ovarian cancer metastasis. 
During the process of ovarian cancer metastasis, malignant cells are shed from the primary 
tumour into the peritoneal cavity. It is here, suspended within ascites fluid, that single-cells 
and multicellular aggregates (spheroids) disperse throughout the peritoneal cavity. 
Widespread secondary metastatic lesions are formed when cells re-attach to mesothelial 
surfaces throughout the peritoneal cavity. 
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anchor as secondary lesions on pelvic organs and at a later stage, metastasize to distant 
organs [39]. Hence, processes such as cell-cell, cell-ECM, localized intraperitoneal 
migration and invasion of the peritoneal lining by spheroids play a dominant role in ovarian 
cancer progression. The molecular mechanisms underlying such metastasis remain poorly 
understood, and effective eradication of peritoneal dissemination remains challenging. 
Therefore, there is an urgent need to develop new treatment modalities, especially targeted 
molecular therapies, through the study of basic biology underlying peritoneal EOC spread.  
1.3 Multicellular spheroids 
 Spheroids as an in vitro model of metastasis 
In order to better comprehend tumour cell biology, it is necessary to utilize in vitro 
models that are able to represent in vivo tumours as precisely as possible. Most current 
information about cancer metastasis and invasion is obtained by the study of cells on 2D 
surfaces. However, monolayer cultures cannot accurately reproduce the behavior of cancer 
cells within solid tumours. In reality, cells are physically organized in 3D patterns 
surrounded by ECM and other cell types, and their behavior is affected by exposure to 
gradients of O2, glucose, and other nutrients, as well as growth factors; as a result, distinct 
transcriptional and biochemical regulation ensues. Thus, 3D tumour spheroid systems have 
been developed and used as an in vitro model to recapitulate the in vivo tumour 
microenvironment and study the initial steps of invasion from a primary tumour [40-42]. 
The 3D organization of cells in spheroids quite faithfully mimics the intercellular 
interactions and the close communications between cells in solid tumours. Several reports 
have described the roles of cadherins (Ca2+-dependent transmembrane proteins that bind to 
each other by homophilic interactions) and integrins (proteins that function as heterodimers 
of α- and β-subunits and act to link cells to ECM proteins) in the spheroid-forming process 
[43-46]. It has been documented in glioma, breast, cervix, and prostate carcinoma cells 
(BMG1, MCF-7, HeLa, and PC3 cell lines) that the acquisition of a 3D structure induces 
alterations in the cellular microenvironment promoting significant changes in tumour 
energy metabolism, proliferation rates, transcription factors, oncogene profile, and drug 
sensitivity compared to conventional 2D cultures [47-51].  
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Spheroid based assays have been shown to better recapitulate drug resistance than 
monolayer cultures [52, 53]. In particular, it has been shown that spheroids are more 
resistant to chemical (antitumour drugs) and physical (ionizing radiation) agents than 
monolayers and that this resistance is comparable to that found in in vivo tumours [54]. 
The development of slower or non-proliferating (quiescent) and hypoxic (sometimes 
necrotic) cells in the inner zones of spheroids also more closely resemble those found in 
tumours. It is therefore advantageous to use 3D spheroid models over 2D culture systems 
for studying the process of tumour metastasis that could pave the way for better treatment 
modalities and perhaps even prevention.  
 Spheroids in ovarian cancer 
Multicellular spheroids are valuable tools for the study of ovarian cancer not only 
because they are a more accurate recapitulation of a solid tumour microenvironment than 
that provided by monolayer culture, but also because of the unique way ovarian cancer 
metastasizes. In the initial steps of EOC dissemination, malignant cells detach from the 
primary tumour directly into the peritoneal space, where single cells do not survive for a 
very long time if they remain alone and must aggregate to other cells in order to survive 
and resist apoptosis, or cell death by detachment, better termed as “anoikis” [55]. The 
aggregation process depends largely on the expression of certain cell-cell interacting 
molecules, which appear dramatically different in spheroids compared to monolayer 
growing cells [56, 57].  
Protected from the surrounding environmental stresses, these aggregates or 
spheroids float within the malignant ascites of the peritoneum, facilitating tumour cell 
invasion into the mesothelium [58]. Iwanicki and colleagues [59] were the first to provide 
evidence that ovarian cancer spheroids “plow” through the protective layer of mesothelial 
cells, leading to mesothelial clearance. Others have corroborated such findings [60], and 
showed that once the cancer cells reach the ECM, they have access to underlying stromal 
cells, which can be recruited to further support their survival and rapid growth. The 
secretion of matrix metalloproteinases (MMPs) by EOC spheroids, specifically MMP2 and 
MMP9, has also been shown to aid in the invasion and degradation of ECM [57, 61]. 
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Furthermore, it’s been shown that in vitro cultured spheroids are capable of tumourigenesis 
in vivo and display a reduced response to chemotherapeutic drugs when compared to 
monolayers [62-64]. EOC spheroids have been shown to undergo reduced proliferation and 
limited drug penetration resulting in decreased susceptibility to chemotherapy [65] and 
hence, are likely the source of recurrent disease. It is well accepted now that spheroids 
represent a significant impediment to successful treatment of late stage EOC [33].  
Though it is apparent that spheroids may make a significant contribution to 
intraperitoneal ovarian cancer spread since they are resistant to anoikis, invade 
mesothelium, and acquire resistance to chemotherapy, much remains to be elucidated 
regarding their complex biology. Since ovarian cancer mortality can be directly attributed 
to disseminated peritoneal mestastasis, gaining a better understanding of spheroid biology 
is crucial in allowing us to identify new treatment opportunities to combat disease spread. 
1.4 EMT 
 Overview of EMT in cancer 
The term epithelial-to-mesenchymal transition (EMT) describes a multi-step event 
during which cells lose numerous epithelial characteristics and gain the properties typical 
for mesenchymal cells. EMT is an essential morphological conversion that occurs during 
embryonic development for complex body patterning. Transitions in cell phenotype from 
epithelial to mesenchymal (EMT) or mesenchymal to epithelial (MET), play a crucial role 
during developmental and physiologic programs that orchestrate events, such as neural 
crest formation, palatal fusion, and wound healing [66, 67]. Under the appropriate 
conditions, epithelial and mesenchymal cells interconvert between these two phenotypes; 
as such, these phenotypes are not always permanent. It is well accepted that the reactivation 
of developmental programs can occur during tumourigenesis, and an analogous plasticity 
of cellular phenotypes occurs in cancers too. In fact, cancer cells in advanced stages 
become aggressive and invasive due to the pathologic initiation of an EMT. Studies on 
human and mouse tumours suggest that the same molecular processes that drive 
developmental EMT are reactivated in the tumour cell to drive tumour progression towards 
invasive metastatic carcinomas [68].  
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Cells undergoing these dynamic transitions, whether under physiologic conditions 
or tumourigenesis, require complex changes in gene expression, cell architecture, and 
migratory and invasive behavior. Typically, epithelial cells involved in an EMT undergo 
dissolution of cell-cell junctions (adherens junctions and desmosomes, tight junctions, and 
gap junctions), lose apical-basolateral polarity, and acquire a mesenchymal phenotype, 
characterized by actin reorganization and stress fiber formation, migration and invasion 
[69-72]. The loss of cell-cell adhesion is a prerequisite of EMT. One of the essential 
molecules for formation and maintenance of the epithelial phenotype is the adhesion 
molecule E-cadherin (encoded by CDH1) which is typically located at cell-cell adherens 
junctions. E-cadherin is a transmembrane glycoprotein which connects through α- and β-
catenin to the actin microfilaments within the cytoplasm, thereby anchoring epithelial cells 
to each other. Loss of E-cadherin is consistently observed during EMT and is currently 
regarded as a hallmark of EMT [67, 73]. Other epithelial markers that may be 
downregulated during this process include ZO-1, claudins, occludin, and cytokeratins. At 
the same time, up regulation of transcription factors such as Snail, Slug, Twist1/2, Zeb1/2, 
as well as mesenchymal markers such as vimentin and fibronectin, can lead to the 
acquisition of cell motility and invasive properties. These changes may further endow 
cancer cells with the ability to secrete proteases that degrade the extracellular matrix and 
migrate to form distant metastases [67, 74-76]. Researchers have used many different 
markers to track pathological EMT, the most commonly reported changes are summarized 
in Table 1.1. Additionally, cytoskeletal elements are reorganized and the peripheral actin 
cytoskeleton is replaced by stress fibers, whereas cytokeratin intermediate filaments are 
replaced by vimentin. Together with gene expression changes, these morphological 
changes transition the cell from a compact, cuboidal (epithelial) shape to a spindle-like, 
fibroblastic (mesenchymal) phenotype. Such transitions render cancer cells to further 
become motile by loosening cell-cell contacts and cell polarity [77].  
Such features of EMT have been observed in a wide variety of different cancer 
models, including ovarian cancer [78-81]. Numerous EMT inducers characterized in cell 
culture systems can initiate metastatic spread in animal models, and in fact correlate with 
poor prognosis in human cancer [82, 83]. For instance, human hepatocellular carcinoma  
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Table 1.1: Classical markers of EMT 
 
(Agiostratidov et al. 2007, Hugo et al. 2007, Venkov et al. 2007, Zeisberg et al. 
2009, Kallergi et al. 2011, Quaggin et al. 2011) 
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(HCC) cell lines harboring both Snail and Twist showed a higher migratory and invasive 
ability in vitro, and co-expression of Snail and Twist indicated the worst outcome in in vivo 
mouse models [84]. Furthermore, Snail or Twist overexpression (associated with 
downregulated E-cadherin and β-catenin expression) was shown in recurrent versus 
primary HCCs specimens, and has been associated with worse progression-free and overall 
survival in patients [84]. Furthermore, invasive and metastatic properties of mouse and 
human tumour cell lines derived from tissues such as breast, colon, liver, skin and oral 
mucosa have shown a direct correlation with Snail expression. Snail has been shown to be 
expressed at the invasive front of skin tumours induced by chemical carcinogenesis in the 
mouse [85-89]. Recent studies have shown that EMT not only endows cancer cells with 
motility to detach from neighboring cells, but also promotes anoikis resistance in cancer 
cells in anchorage-independent circumstances [90, 91]. Slug-mediated EMT was found to 
promote cell motility and contribute to the acquisition of anoikis resistance in human 
adenoid cystic carcinoma cells [92]. 
Emerging evidence also suggests that EMT may be associated with the acquisition 
of chemotherapeutic resistance. Colon carcinoma cell lines resistant to oxaliplatin were 
shown to exhibit a mesenchymal morphology and express several markers of EMT [93]. 
Suppression of Twist in the lung carcinoma cell line A549 resulted in increased 
chemosensitivity to cisplatin [94]. Snail expression has been shown to confer resistance to 
paclitaxel, adriamycin, and radiation by antagonizing p53-mediated apoptosis [95, 96]. 
Increased expression of Zeb1 and decreased expression of E-cadherin have been associated 
with drug resistant pancreatic cell lines, and reduction of Zeb1 expression has been 
implicated in increased drug sensitivity [97]. Twist and one of its target genes were shown 
to be elevated in a subset of MCF7 or MDA-MB434 breast cancer cells selected for their 
invasive properties, and, having undergone EMT, they were also resistant to paclitaxel 
[98]. Moreover, the depletion of Twist can partially reverse multidrug resistance in breast 
cancer cells [99].  
Other studies have also shown EMT induced by EGFR signalling to be linked to 
tamoxifen resistance and increased invasiveness of MCF7 breast cancer cells [100, 101]. 
Evidence from several other groups have further demonstrated that the induction of EMT 
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in breast cancer cells results in the acquisition of stem-like properties , including the ability 
to form mammospheres in culture and to resist the cytotoxic effects of chemotherapy [102, 
103]. This idea that EMT can induce stem cell-like properties in cancer cells is largely 
growing and continues to be tested in a variety of different cancers, including EOC. 
Altogether, the expression of EMT signalling pathways has been associated with cancer 
progression, relapse and poor prognosis in various epithelial cancers, including breast, 
pancreas, colon, prostate, and ovarian cancer [104-106]. The EMT program seems to give 
carcinoma cells the phenotypic traits necessary for invasion and metastasis as well as for 
resistance to cancer therapies. Targeting the molecular activators of EMT and downstream 
transcriptional regulators of EMT are thus hypothesized to be a potentially effective way 
of treating cancer patients. 
 Regulation of EMT 
EMT is controlled by a network of signalling and transcriptional events. Not 
surprisingly, many of the same signalling pathways and transcription factors important to 
physiologic instances of EMT are also activated during pathologic EMT. A variety of 
cytokines and growth factors are induced during EMT, which further stimulate the EMT 
process and promote cell migration and invasion; these factors include transforming growth 
factor β (TGFβ), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), 
hepatocyte growth factor (HGF), Wnt, Notch ligands, and others [107-109]. Hypoxia can 
also induce EMT in tumours through the up regulation of hypoxia-inducible factor-1α 
(HIFα), which affects transcription of target genes [110]. Although several growth factors 
participate in EMT, TGFβ is the prototypical inducer of EMT, and is the most studied 
[111].   
The process of EMT is further regulated by several transcriptional suppressor 
families. These ‘master regulators’ of EMT include the zinc finger proteins Snail/SNAI1 
and Slug/SNAI2, the two-handed zinc finger family factors Zeb1/ZEB1 and Zeb2/ZEB2, 
and the basic helix-loop-helix factors Twist1/TWIST1 and Twist2/TWIST2 [112-114]. All 
of these transcription factors have been shown to be involved in disrupting epithelial 
homeostasis by destabilizing cell-cell contacts, a critical step in EMT. For example, the 
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SNAI and ZEB family of transcription factors can bind directly to the E-cadherin promoter 
to repress gene transcription [115]. Previous studies demonstrated that this is mediated by 
specific binding to E-box sequences within the CDH1 promoter [116]. Snail is the first 
discovered and most important transcriptional repressor of CDH1. Snail induces repressive 
histone modifications at the CDH1 promoter through the recruitment of co-repressors and 
different proteins, such as histone deacetylase 1 (HDAC1) and HDAC2 [117]. Activation 
of the TGFβ pathway itself can recruit Snail [118], Zeb [119], or Twist [120] to repress 
epithelial genes. TGFβ/Smad pathway can transcriptionally induce Snail expression by 
directly binding to the SNAI1 promoter. 
During the progression of EMT, it is believed that Snail will be the first factor to 
become active to initiate the transition whereas Slug would be expressed in later stages to 
allow the cells to retain their mesenchymal characteristics [121]. Snail has been shown to 
be sufﬁcient to induce EMT and the expression of EMT associated genes, suggesting that 
Snail may act as the switch to promote the EMT program in epithelial cells [112]. For 
instance, in tumours that express Snail, ZEB gene activation frequently occurs upon SNAI1 
gene transcription [122]. Some studies have demonstrated that ectopic expression of Snail 
alone can promote an EMT in epithelial tumour cell lines [88, 89]. Snail not only represses 
CDH1 expression through direct binding to E-boxes; other genes that may also be 
negatively regulated by Snail include cytokeratin 18, desmoplakin, MUC1, claudin, and 
occludin, whereas the expression of matrix metalloproteinases, vimentin, ﬁbronectin, and 
Rho GTPases can be induced by Snail during EMT [112, 123, 124]. The transcriptional 
repressor activity of Snail is modulated by its expression level and intracellular 
localization. For example, as previously mentioned, certain growth factors/signalling 
pathways (such as TGFβ) can modulate snail expression. In terms of localization, p21-
activated kinase (Pak1), a serine/threonine protein kinase, can regulate Snail through 
phosphorylation at Ser246, causing Snail to accumulate in the nucleus where it is most 
stable and resulting in enhanced transcriptional activity. Cytoplasmic Snail, on the other 
hand, has a very short half-life as it is targeted for ubiquitin-mediated proteasome 
degradation by glycogen synthase kinase-3β (GSK-3β) induced phosphorylation [125]. 
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Several recent studies have also recognized the role of non-coding RNAs in 
activating the EMT program in cancers [126]. In this context, the role of miR-200 family 
has been well characterized in regulating EMT [127]. Expression of the miR-200 family is 
strongly associated with epithelial differentiation, and a reciprocal feedback loop between 
the miR-200 family and the ZEB family of transcription factors tightly controls both EMT 
and MET [127, 128]. The miR-200 family members, considered to be tumour suppressive 
miRNAs, have been shown to be downregulated in a variety of different cancers including 
bladder, gastric, head and neck, and ovarian cancer [129-133]. Other microRNAs 
considered to be oncogenic have also been indicated in the regulation of EMT.  
 EMT in ovarian cancer 
Among the panel of solid tumours that EMT has been implicated to play crucial 
roles, EOC is probably among the least understood and studied. The clinical relevance of 
EMT in ovarian cancer development and progression is not fully understood, in part, owing 
to conﬂicting results with EMT marker gene expression patterns and clinical outcomes. For 
example, the loss of E-cadherin may correlate with poor survival [134, 135], but in an 
additional large-scale study the opposite correlation in high-grade EOC was observed 
[136]. EOC represents a heterogeneous disease entity with unique biology [137]. Unlike 
other carcinomas, many EOC tumours have been shown to co-express epithelial and 
mesenchymal determinants to begin with [138, 139]. Nevertheless, recently, there has been 
an increase in findings implicating EMT in ovarian carcinoma and in promoting EOC 
aggressiveness [139-141]. It has been suggested that primary EOC may undergo an EMT-
like process during localized invasion in the peritoneum and retain mesenchymal features 
in advanced tumours [142].  
The shedding of cancerous cells from the primary tumour into the peritoneal cavity 
is the first step of the metastatic spread. This peritoneal spread of ovarian cancer to 
surrounding organs within the abdomen relies on the movement of cancer cells, which can 
be regulated in an autocrine manner, or in a paracrine manner by growth factors and 
cytokines present in the surrounding microenvironment or peritoneal fluid [143]. In this 
context, the contribution of EMT by endogenous or exogenous growth factors is vital to 
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initiate and sustain abdominal cell motility of tumour cells. In fact, similar to other cancers, 
there are studies in the literature indicating that signalling pathways such as the TGFβ, 
EGF, JAK/STAT, MAPK, ERK, AKT and other cytokines present in ascites fluid can 
either trigger or stabilize EMT in ovarian cancer cells, contributing to a more motile and 
aggressive phenotype [144-149]. Thus, more recent studies support the hypothesis that 
induction of the EMT program is important for ovarian cancer progression and metastasis 
[150], however, the exact underlying mechanisms of EMT-mediated EOC metastasis needs 
further research, especially in the context of spheroid cell dissemination.   
As with other cancers, emerging evidence suggests that EMT plays a crucial role 
in the progression of EOC not only by increasing cancer cell motility, but also by inducing 
chemo-resistance, and cancer stem cell characteristics [151, 152]. Ovarian carcinoma cells 
that are resistant to paclitaxel have been shown to exhibit relatively high expression of 
Twist and Snail and loss of an epithelial phenotype. These paclitaxel-resistant EOC cells 
further displayed enhanced motile and invasive behavior in vitro and increased formation 
of peritoneal metastasis in a mouse model compared to their paclitaxel-sensitive 
counterparts [153]. Exposure of clinical specimens from patients diagnosed with late-stage 
ovarian cancer to cisplatin, as well as the OVCA433 cell line, showed reduced expression 
of CDH1 and increased SNAI1, SNAI2, TWIST, and VIM (vimentin) mRNA levels, as well 
as increased expression of cell surface stem cell markers [154]. In another study using EOC 
cell lines, upregulation of Snail and Slug have been correlated with resistance to radiation 
and paclitaxel and shown to directly participate in pro-survival signalling and acquisition 
of stem-like characteristics [96]. Another study demonstrated, through the use the A2780 
ovarian cancer cell line, and its cisplatin-resistant daughter line, A2780cis, that EMT 
related genes directly contribute to cisplatin-resistance in ovarian cancer. Furthermore, 
knockdown of SNAI1 and SNAI2 in A2780cis showed reversal of the EMT phenotype and 
restoration of cisplatin sensitivity [155]. The same study assessed a cohort of primary 
ovarian tumours and their resulting gene expression data mirrored the finding that an EMT-
like pathway is activated in resistant tumours relative to sensitive tumours.  
Thus, it is not surprising that the induction of EMT in EOC is associated with poor 
prognosis [156]. In a review summarizing gene expression array analyses, EMT 
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(sometimes associated with TGF-β signalling) was shown to be a main driver of poor 
survival in EOC patients [157]. Authors of this review showed that amongst 154 genes 
highly up-regulated or down-regulated in aggressive EOC, 108 (70.1%) genes were 
associated with EMT. Another study showed that the expression of E-cadherin 
transcriptional repressors increased with advanced malignancy, and the prognosis of 
ovarian carcinoma patients positive for Snail expression was poorer than that of negative 
patients [158]. In a series of 143 ovarian cancer patients, a recent study showed that high 
expression of ZEB2 mRNA significantly correlated with a poor prognosis in terms of both 
overall survival and progression-free survival [159]. Pathways or expression profiling 
signatures enriched in EMT genes have been identified to distinguish subgroups of EOC 
with worse clinical survival outcomes [160]. Therefore, targeting EMT in EOC might be a 
feasible and effective therapeutic option.  
 Snail/SNAI1 in ovarian cancer 
The zinc ﬁnger factor Snail belongs to the Snail superfamily of transcriptional 
repressors [123, 124], in which other members associated with EMT are found, such as 
Slug. Given that Snail is an important initiator of EMT [121], it is not surprising that this 
transcription factor is linked to the aggressive behavior of ovarian cancer cells. Snail is 
perhaps one of the most important transcription factors, not only because it acts primarily 
as a key inducer of EMT, but also because it is strongly correlated with tumour recurrence, 
cell survival, immune regulation and stem cell biology [125]. However, Snail’s role in the 
pathobiology of EOC is understudied in 3D cell culture systems.  
In 2D experimental models of EOC, Snail was shown to mediate E-cadherin 
downregulation induced by hypoxia [161], promote tumour growth and metastasis [162], 
induce EMT initiated by p70 S6 kinase and BMP4 [163, 164], and mediate invasion [165]. 
Ectopically expressed SNAI1 or SNAI2 induced EMT in serous adenocarcinoma SKOV3 
cells and enhanced motility, invasiveness and tumourigenicity. In this model, Snail was 
shown to suppress expression of adherens and tight junction components, while Slug 
further suppressed expression of desmosomes [165]. In an ovarian cancer clear cell 
carcinoma cell line (ES-2), SNAI1 shRNA-expression reduced invasion and MMP-2 
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activity by these cells [166]. Another study deleted Snail in a serous adenocarcinoma cell 
line (RMG1) using the CRISPR/Cas9 system and showed that SNAI1 regulates actin 
cytoskeletal structure and cell migration, as well as cell-substrate adhesion [167]. 
Furthermore, silencing of Pak1 (which regulates nuclear localization of Snail) in ES-2 and 
high-grade serous OVCAR3 cells, using dominant negative (DN) clones, showed that the 
latter had reduced attachment to ECM proteins (laminin, fibronectin, collagen I and IV), 
invasion, and MMP-2 activity compared to constitutively active (CA) and wild-type ES-2 
cells and OVCAR3 cells. DN Pak1 ES-2 cells additionally had reduced binding to LP9 
cells, a normal human mesothelial cell line generated from benign mesothelium [166]. 
Snail up-regulation has also been linked to the increased invasiveness in EOC cells induced 
by 17beta-Estradiol (E2) [168]. Depletion of endogenous Snail using siRNA attenuated E2 
mediated decreases in E-cadherin expression, migration and invasion in EOC cells [169]. 
All of these studies help us gain an appreciation for the Snail’s role in 2D cell culture 
systems, however, very little is known about the functional role of Snail in EOC spheroids.  
Snail expression and its clinical role has been the subject of several studies. One 
study showed Snail expression to be predominant in serous and endometrioid primary 
adenocarcinomas by immunohistochemistry, and found correlations between Snail 
expression, chemoresistance, and poor prognosis [170]. Other clinical studies, however, 
have reported that Snail represses E-cadherin in primary carcinomas and its expression is 
increased in metastases; these observations were associated with shorter overall survival 
[171]. Others have also found signiﬁcantly higher Snail expression in solid metastases, as 
well as primary carcinomas from patients diagnosed with late-stage ovarian cancer (III and 
IV) compared with early-stage ovarian cancer, and Snail was observed to be more often 
localized to the nucleus in advanced-stage compared to early-stage cancers [162]. Another 
group reported similar findings where expression levels of Snail, fibronectin and N-
cadherin in stage III and IV EOC tissues were higher than those in stage I and II, whereas 
expression of E-cadherin and β-catenin decreased with advanced stage of disease [172]. 
High Snail expression in primary carcinomas has been associated with greater risk of death 
[173]. Nuclear expression of Snail in EOC tumours was further shown to be significantly 
higher in patients with peritoneal dissemination than in those without, associating Snail 
with both progression-free survival and overall survival in ovarian cancer patients [174]. 
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Taken together, along with evidence that Snail contributes to multiple aspects of 
therapeutic resistance [96, 155], it is unquestionably crucial to investigate the functional 
role of SNAI1 in the progression of EOC, especially in the context of the spheroid, that 
could perhaps pave the way for better therapeutic strategies in the treatment of this disease.  
1.5 TGFβ signalling 
 Overview 
Transforming growth factor beta (TGFβ) ligands are members of the TGFβ 
superfamily of signaling molecules, a family which is comprised of more than 30 closely 
related proteins including bone morphogenetic proteins (BMPs), activins, inhibins and 
nodal [175]. TGFβ is a multipotent cytokine that is involved in many diverse cellular 
processes such as cell growth (inhibition/proliferation), differentiation, apoptosis, 
migration, invasion, EMT, extracellular matrix (ECM) remodeling, immune-suppression, 
and embryogenesis in mammals [176]. The complicated role of TGFβ in mediating these 
cellular activities depends on cell types, growth environment, concentration of ligands, and 
the presence of other growth factors [177-179]. Under normal circumstances, dynamic 
regulation of TGFβs is important during embryonic development and for maintaining adult 
tissue homeostasis. However, in disease states (e.g., cancer, fibrosis, and inflammation) 
excessive production of TGFβ drives disease progression by modulating cell growth, 
migration or phenotype. Studying the TGFβ signalling pathway has therefore been crucial 
in unravelling many of the key steps in cancer metastasis. This section will discuss TGFβ 
signal transduction, how this pathway is regulated as well as its role in various cancers, 
including ovarian cancer. 
 Pathway activation 
In humans, three isoforms of TGFβ, which share 75% amino acid sequence 
homology (TGFβ1, TGFβ2 and TGFβ3) have been described [180, 181]. TGFβ1 (the 
prototypic form) is the most abundant in most tissues. TGFβ1 and TGFβ3 isotypes are 
expressed in adult tissues, whereas TGFβ2 expression occurs mainly during development 
and differentiation [175, 182, 183]. TGFβ ligands are secreted from the cell as homodimers 
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in their latent precursor form, which cannot bind to its receptor until proteolytically cleaved 
to their active form.  
The canonical TGFβ signalling pathway is activated when mature TGFβ 
homodimers bind either directly to TGFβ type II receptor (TβRII) or indirectly by binding 
to β glycan (TβRIII) which then presents the TGFβ homodimers to TβRII. Activated TβRII 
in turn recruits and activates TGFβ type I receptor (TβRI/ALK5). This active receptor 
complex composed of two type I and two type II receptors phosphorylates and activates 
the receptor-activated Smads (R-Smad), Smad2 and Smad3 [181, 184]. Activated R-Smads 
then form complexes with the common mediator Smad (co-Smad): Smad 4. This 
heteromeric Smad complex then translocates to the nucleus and, along with other DNA 
binding cofactors, mediates gene transcription by high affinity binding to Smad-binding 
elements (SBE) in the promoters of its target genes [185] (Figure 1.2). The output of a 
TGFβ response is highly contextual throughout development, across different tissues, and 
in cancer [111].  
 Pathway attenuation 
The inhibitory SMADs (I-SMADs: such as SMAD7) negatively regulate TGFβ 
signalling by competing with R-SMADs for type I receptor or inhibiting the R-SMAD - 
co-SMAD complex [186, 187]. I-SMADs can also promote proteasomal degradation of R-
SMADs and co-SMADs through complex formation with ubiquitin ligases (Smurf1/2) 
[188-190]. I-SMADs may also antagonize R-SMAD activation by recruiting specific 
phosphatases to the activated receptor complex, targeting it for dephosphorylation. In 
addition to being regulated by phosphorylation and ubiquitination, the TGFβ signalling 
pathway can also be regulated by transcriptional co-repressors (i.e. SnoN/SkiL and EVI1) 
[191, 192]. 
 Smad-independent signalling 
TGFβ signalling is even more complicated. The TGFβ-TβRI-TβRII complex can 
also signal through mechanisms independent of Smad activation. Activation of non- 
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Figure 1.2: Canonical TGFβ signalling pathway. 
The canonical TGFβ signalling pathway is activated when active TGFβ binds either 
directly to TGFβ type II receptor (TβRII) or indirectly by binding to β glycan (TβRIII) 
which then presents the TGFβ to TβRII. Activated TβRII then recruits and activates the 
type I receptor (TβRI/ALK5). This active receptor complex composed of two type I and 
two type II receptors phosphorylates and activates the receptor-activated Smads (R-Smad), 
Smad2 and Smad3. Activated R-Smads then form complexes with the co-Smad: Smad 4. 
This heteromeric Smad complex then translocates to the nucleus and mediates gene 
transcription by binding to Smad-binding elements (SBE) in the promoters of its target 
genes.  
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canonical signalling pathways may include the PI3 kinase, ERK/MAPK, 
TRAF/TAK1/JNK and RhoA/ROCK pathways [191-193]. Moreover, TGFβ signalling 
output can be strongly influenced by intersecting signalling pathways, such as Ras, Notch 
and Wnt, and by crosstalk between other ligands, receptors, and SMADs of the TGF-β 
superfamily [194]. The crosstalk between TGFβ signalling and other signalling pathways 
is highly context-dependent and could have important implications in cancer [195]. 
 TGFβ signalling in cancer 
Many advanced tumours produce excessive amounts of TGFβ which, in normal 
epithelial cells, is a potent growth inhibitor and plays an important function in normal tissue 
homeostasis [181, 196, 197]. However, in oncogenically activated cells, the homeostatic 
action of TGFβ is often diverted along alternative pathways. The current consensus is that 
TGFβ signalling has a dual role in cancer: while TGFβ signalling elicits protective or 
tumour suppressive effects during the early growth-sensitive stages of tumourigenesis 
[197-210], later in tumour development (when tumour cells become refractory to TGFβ-
mediated growth inhibition) the TGFβ pathway is utilized for its tumour progressing effects 
[211]. During the early stages of epithelial tumourigenesis, TGFβ inhibits tumour 
development and growth by inducing cell cycle arrest, senescence, and apoptosis; this aids 
in maintaining cellular homeostasis critical for the prevention of continuous cell 
proliferation and thus tumour formation [191]. At late stages of malignancy, TGFβ 
overload drives malignant progression and metastasis through three broad biological 
effects: dampening of immune surveillance [212]; indirect facilitation of tumour cell 
proliferation (via its effects on the microenvironment - stromal fibroblasts, ECM, and 
angiogenesis - that in turn modulate the tumour cell) [111, 213, 214]; and cell induction of 
EMT, which will be the focus of my thesis [215].  
TGFβ1, specifically, is secreted in abundance in many advanced human and murine 
tumours [216-221]. Overexpression of this ligand has been shown to drive metastasis in 
mouse mammary and skin tumour models [200, 203, 222, 223], melanoma, prostate cancer, 
colon cancer, as well as many other tumour types [213, 224, 225]. TGFβ in tumours may 
be produced by cancer cells or by stromal components. In fact, presence of TGFβ in the  
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tumour microenvironment has been shown to play a prominent role in cancer metastasis. 
The most vivid example is the bone, with it being a rich store of multiple growth factors 
including TGFβ, and a common site of dissemination for both breast and prostate cancers 
[226-228]. Enhanced TGFβ signalling leading to pathogenesis could be mediated in many 
other ways. For example, one study identified USP15 (a deubiquitinating enzyme) to 
correlate with high TGFβ activity by binding to the SMAD7-SMURF2 complex, thereby 
stabilizing TβRI. The USP15 gene was found amplified in glioblastoma, breast and ovarian 
cancer [229] and conferred poor prognosis in individuals with glioblastoma. Findings from 
other studies have also identified the TGFβ pathway to be highly active in high-grade 
glioma, and elevated TGFβ activity further confers poor prognosis in individuals with 
glioma [230, 231]. The prognostic signiﬁcance of TGFβ ligands and downstream signalling 
mediators has also been investigated in several other cancer studies. For example, advanced 
stages of breast cancer have been associated with elevated TGFβ1 serum levels [232], and 
high tissue levels of TGFβ1 has been associated with increased lymph node metastasis and 
an unfavorable prognosis in breast cancer patients [233, 234].  
TGFβ has long been known to be a major inducer of EMT particularly in heart 
formation and palate fusion in mice, as well as in some mammary cell lines, and in mouse 
models of skin carcinogenesis [215, 235]. In human cancers, TGFβ can promote metastasis 
via the induction of EMT. Characteristics of EMT have been observed in pathology 
sections of human cancers, particularly at the invasion front, a location that is rich in 
stromal TGFβ and other cytokines that may cooperate in the induction of EMT [236]. 
TGFβ-dependent EMT in cancer cells is mediated, in part, by the ability of TGFβ to alter 
cell junctions [237-239]. Mouse mammary epithelial cells treated with TGFβ were shown 
to downregulate the expression of the epithelial markers E-cadherin, ZO-1, desmoplakins 
I/II and increase the expression of the mesenchymal marker fibronectin [237]. TGFβ-
induced EMT has been observed in A549 pulmonary adenocarcinoma cells as well as other 
cancer cell lines [240, 241].  
In addition to its role in enhancing invasion and migration, as alluded to earlier, 
EMT inducing factors such as TGFβ and its downstream targets (Twist and Snail) may also 
promote the expression of stem-like cell surface markers [103]. Earlier work has shown 
23 
 
that breast cancer stem cells, identified by the CD44hi/CD24lo marker, overexpress 
components of the TGFβ pathway. When these cells were treated with a TβRI kinase 
inhibitor, these stem cells shed their mesenchymal traits to take on a more epithelial 
phenotype [242].  
 TGFβ signalling in ovarian cancer 
In many cancers including head and neck, breast, lung, esophageal, gastric, colon 
and pancreatic cancers, resistance to TGFβ’s antiproliferative effects has been linked to 
pathway mutations such as TGFβ receptor I or II (TβRI or TβRII) or Smad 2 and 4 
mutations [243-247]; however, in ovarian cancer, TGFβ receptor and Smad mutations are 
infrequent events [248-251]. In the few cases where receptor and Smad mutations have 
been described, it is unknown whether these mutations alter protein function [248, 252, 
253]. Unlike pancreatic cancer in which ~50% of SMAD4 is mutated [191], reports of the 
presence of SMAD4 variants in ovarian cancers are lacking [254]. Polymorphisms in 
SMADs 2, 6, 7, have been found, however not associated with any amino acid change and 
therefore unlikely to be significant in the development of ovarian cancer [248, 249]. Results 
from two separate studies have shown TβRII is not a major mutation target in ovarian 
cancer [255, 256], whereas another group found that TβRII mutations were significantly 
associated with clear cell carcinomas [257]. Other groups have shown that, although 
ovarian carcinomas are resistant to the antimitogenic effects of TGFβ, the TGFβ/Smad 
pathway remains intact and functional in ovarian cancer cells [258-260]. Since the core 
pathway components are rarely lost or mutated in ovarian cancer, these results suggest that 
disruption of TGFβ signalling in ovarian cancer occurs by other mechanisms.   
Although TGFβ plays an important role in normal ovarian physiology, there 
appears to be discrepancies in the literature regarding its role in ovarian cancer progression. 
For example, some studies show the type II receptor and SMAD4 to be downregulated in 
ovarian cancer [261]; and negative regulators of TGFβ signalling (such as SMAD7) are 
overexpressed [259, 262], suggesting that suppression of TGFβ signalling is crucial for 
ovarian carcinogenesis. However, other studies show that overexpression of TGFβ 
signalling components, such as SMAD3, is associated with increased metastatic potential 
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and poor prognosis in ovarian cancer [263]. As stated above, TGFβ signalling functions as 
a double-edged sword in cancer development, a tumour suppressor in early tumourigenesis 
but a tumour enhancer in advanced stage cancer. How TGFβ plays a certain role in one cell 
but a different role in its malignant counterpart is not fully understood. It is likely that 
ovarian cancer cells derive a selective advantage by keeping a functional tumour-
promoting TGFβ signalling pathway while repressing TGFβ antiproliferative responses.  
As such, TGFβ1 is specifically thought to play a role in the pathobiological 
progression of ovarian cancer because this cytokine is overexpressed in cancer tissue, 
plasma, and peritoneal fluid of ovarian cancer patients [263-265]. Moreover, all three 
TGFβ ligands have been found to be markedly elevated in ovarian cancer cells [266] and 
primary ovarian cancer specimens [267]; and mRNA levels of both TGFβ1 and TGFβ3 
have been shown to be increased in recurrent ovarian cancers [268]. Quantitative 
immunohistochemical analysis in another report showed increased TGFβ1 and TGFβ2 
expression in both primary and metastatic tumour specimens compared to normal ovarian 
tissue [269]. Increased expression of TGFβ has been shown to be associated with peritoneal 
metastasis, expression of VEGF, and microvessel density and thus correlated with poor 
patient survival [270]. Higher Smad3 expression in ovarian carcinoma has also been shown 
to be correlated with poor survival [263, 271]. While some studies support a positive 
association between TGFβ1 expression and prognosis in EOC [270], other studies have 
found no association [272]. Nevertheless, one study that analyzed the publicly available 
microarray dataset (GSE2109) found the TGFβ signalling pathway to be activated in 
omental metastases as compared to primary sites of disease [273]. Omental metastasis is 
the most frequent site of metastasis and an important prognostic factor in advanced ovarian 
cancer. Through immunohistochemical analysis, authors of this study found both TβRII 
and phosphorylated SMAD2 to be increased in omental metastases as compared to primary 
disease sites [273]. 
Moreover, TGFβ signalling pathway likely plays an important role as a marker or 
mediator of chemoresistance in advanced serous ovarian cancer [274]. TGFβ1 mRNA 
expression was found to be significantly lower in tumours with high sensitivity to paclitaxel 
and carboplatin than in those with low sensitivity; and those patients whose tumours 
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showed low expression tended to have a better prognosis than those whose tumours showed 
high TGFβ1 mRNA expression [275]. Another study found that although the serum level 
of TGFβ1 had no diagnostic and prognostic role in EOC patients, it was associated with 
sensitivity to standard chemotherapy. Elevated serum TGFβ1 level was found to be 
associated with metastatic disease; and chemotherapy unresponsive patients had higher 
serum TGFβ1 levels compared with responsive ones [276]. Furthermore, a recent pathway 
analysis of data from nine gene proﬁling array studies, in which ovarian carcinoma 
resistance to platinum-based chemotherapy was studied, implicated the TGFβ pathway 
(which affected both EMT and stemness) as one of the main drivers of chemoresistance in 
ovarian carcinoma [277]. 
There is growing evidence in the literature to support that TGFβ signalling may 
enhance the metastatic potential of ovarian cancer through mediating epithelial to 
mesenchymal plasticity. However, most of these studies are limited to 2D culture systems. 
For example, TGFβ1 has been shown to elevate matrix metalloproteinase secretion and 
invasion through Matrigel in ovarian cancer cells [278, 279]. All three TGFβ isoforms 
induced secretion of MMPs, loss of cell-cell junctions, down-regulation of E-cadherin, up 
regulation of N-cadherin, and acquisition of a fibroblastoid phenotype in the OVCA429 
cell line [263]. A subsequent study corroborated these findings and showed that TGFβ 
treatment of OVCA429 cells induced the expression of Snail and Slug, repressed the 
expression of E-cadherin, and increased the production of MMP2. The EMT phenotype 
and invasiveness of these cells was further augmented by additional treatment with EGF 
[280]. Other reports have demonstrated that TGFβ treatment of the SKOV3 ovarian cancer 
cell line stimulated re-organization of the actin cytoskeleton triggering stress fibers and 
cellular protrusion formation [78], and decreased the expression of E-cadherin while 
increasing N-cadherin and expression of vimentin [281]. TGFβ target genes, such as Id-1, 
was shown to mediate a motile and invasive EMT phenotype in SKOV3 and 3AO ovarian 
cancer cells as knockdown of Id-1 inhibited these changes [281]. Another study reported 
that TGFβ1 induces EMT in two ovarian adenosarcoma cell lines, derived from a rare 
variant of a mixed-Mullerian tumour [282].  
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One study proposed a unique mechanism by which the TGFβ signalling pathway 
played an active role in high-grade serous EOC progression. They identified miR-181a as 
an inducer of TGFβ-mediated EMT, via suppression of Smad7 [283]. Data from a large-
scale analysis of numerous high-grade serous ovarian cancer samples suggests that 
acquisition of invasiveness in ovarian cancer cells is accompanied by the emergence of a 
mesenchymal subtype of tumours with a TGFβ gene signature that is associated with poor 
patient outcome [284]. Although some studies have uncovered an association between 
EOC outcome and TGFβ-mediated EMT, much remains to be elucidated about how this 
ligand contributes to spheroid-mediated ovarian cancer progression, particularly in the 
regulation of an EMT.  
1.6 Scope of Thesis 
The presence of peritoneal metastases in EOC, mainly mediated by spheroid 
formation and dissemination, is a common and adverse event associated with poor 
prognosis. Cells from the primary tumour shed into the peritoneal cavity and must survive 
under non-adherent conditions until they reach the serosal surface of various abdominal 
organs, upon which they are able to reattach and form secondary metastatic lesions. Our 
lab has developed an in vitro model system to mimic suspension-induced spheroid 
formation and re-implantation to an adherent substratum. Herein, we provide the first 
report indicating that spheroid formation alone has the capacity to drive EMT in patient 
ascites-derived EOC cells, and this is regulated by endogenous TGFβ signalling (Chapter 
2). We continue to investigate the role of Snail/SNAI1 downstream TGFβ signalling in 
EOC spheroid formation and metastasis (Chapter 3) as we observed this protein to be 
robustly upregulated during spheroid formation, and we hypothesized this to be a crucial 
factor in the acquisition of an aggressive phenotype in EOC.  
Given the unique way EOC metastasizes, it is particularly important to understand 
the biology of these more aggressive aggregates in order to prevent or hamper formation 
of deadly peritoneal metastasis. However, there remains a paucity of literature that explores 
basic biological phenomena and altered signalling pathways in EOC spheroids, as most 
studies have frequently employed 2D culture systems for the study of tumour migration 
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and invasion. As such, our studies have all been performed in a biologically-relevant 3D 
model system, which reveal some of the complex molecular mechanisms that mediate EOC 
invasion and metastasis. Our findings may therefore shed light into the identification of 
novel targeted therapies for the management of EOC metastasis.  
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Chapter 2 
2 TGFβ SIGNALLING REGULATES EPITHELIAL-MESENCHYMAL 
PLASTICITY IN OVARIAN CANCER ASCITES-DERIVED SPHEROIDS  
2.1 Introduction 
Epithelial ovarian cancer (EOC) is the most lethal of the gynaecologic malignancies 
in women [1, 2]. Early detection significantly enhances survival; however, more than 75% 
of patients present at first diagnosis with advanced stage disease when the tumour has 
already metastasized beyond the primary site [3]. EOC is unique among carcinomas in that 
it very rarely leads to blood-borne metastasis; rather, malignant cells are shed from the 
primary tumour directly into the peritoneal cavity. Malignant cells aggregate and survive 
in the peritoneal fluid, often in the form of ascites, as spheroid-like structures. These 
spheroids then attack and invade the peritoneum, seed metastatic tumour growth, and are 
resistant to standard chemotherapeutics. Extensive seeding of these spheroids are 
frequently observed on the uterus, sigmoid colon and omentum in advanced-stage and 
recurrent disease [4, 5]. Thus, a better understanding of EOC spheroid biology may 
elucidate important mechanisms involved in the metastasis of this complex disease. 
It has been proposed that EOC cells are able to switch between epithelial and 
mesenchymal states during metastasis [6].  For most carcinomas, progression toward 
malignancy is accompanied by loss of epithelial differentiation and a shift towards a 
mesenchymal phenotype [7]. It is well-established that this occurs through epithelial-
mesenchymal transition (EMT), the mechanism believed to help tumour cells in their 
ability to migrate, invade, and metastasize [8, 9]. EMT is an essential morphologic 
conversion that occurs during embryonic development for complex body patterning. EMT 
occurs when epithelial cells lose their epithelial cell characteristics, including dissolution 
of cell-cell junctions (tight junctions, adherens junctions, and desmosomes), lose apical-
basolateral polarity, and acquire a mesenchymal phenotype, characterized by actin 
reorganization and stress fiber formation, migration and invasion [10, 11]. The loss of cell-
cell adhesion is a prerequisite of EMT, a hallmark of which is the functional loss of E-
cadherin [4]. Emerging evidence suggests that EMT plays a crucial role in the progression 
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of EOC by increasing cancer cell motility, chemo-resistance, and cancer stem cell 
characteristics [12]. 
In EOC, signals from the neoplastic microenvironment, including a variety of 
cytokines and growth factors, function to control EMT. Although several growth factors 
participate in EMT, transforming growth factor-beta (TGFβ) has been the most studied. 
The TGFβ superfamily consists of a large number of structurally related polypeptide 
growth factors, including TGFβ, bone morphogenetic protein (BMP), inhibin/activin and 
Mullerian inhibiting substance (MIS) families; each is capable of regulating a broad 
spectrum of cellular processes, including cell proliferation, lineage determination, 
differentiation, motility, adhesion, embryogenesis, fibrosis, immunosuppression and 
apoptosis [13]. TGFβ signalling has been implicated in the pathogenesis of many different 
cancers, including EOC [9, 14]. Indeed, TGFβ is thought to play a role in the 
pathobiological progression of EOC because this cytokine is overexpressed in cancer 
tissue, plasma, and peritoneal fluid of ovarian cancer patients [15].  
We have discovered that patient ascites-derived EOC cells naturally undergo a 
robust EMT response by simply aggregating into spheroids, and this was reversed upon 
spheroid re-attachment to a substratum. Given that TGFβ is a key regulator of EMT in 
carcinomas [16], we investigated its role in spheroid-induced EMT and found that 
treatment with the TβRI inhibitor, SB-431542, potently blocked endogenous EMT in 
spheroids. Additionally, SB-431542 treatment upon spheroid re-attachment further 
enhanced the epithelial phenotype of dispersing cells while decreasing cell motility and 
migration. In fact, spheroid formation was compromised by exposure to SB-431542, and 
this rendered cells susceptible to carboplatin-induced cell death.  
2.2 Material and Methods 
 Cell culture 
Ascites fluid obtained from ovarian cancer patients at the time of debulking surgery 
or paracentesis was used to generate primary cell cultures as described previously [17]. 
Briefly, bulk ascites containing cells was mixed 1:1 with growth medium [MCDB105 
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(Sigma, St. Louis, MO) / M199 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) (Wisent, St. Bruno, Quebec, Canada) and 50 µg/ml penicillin-
streptomycin]. Cells were grown in a 37°C humidified atmosphere of 95% air and 5% CO2. 
To account for inter-patient variability and the finite lifespan of primary ascites-derived 
cells, many independent samples collected from patients with high-grade EOC were used 
throughout the study (Supplementary Table S1). Experiments were performed using cells 
between passages 3 and 5 and performed with at least four independent patient samples 
and at least three experimental replicates. Samples have been confirmed independently to 
have greater than 90% EpCAM-positive cells beyond passage 2. All patient-derived cells 
were used in accordance with institutional human research ethics board approval (UWO 
HSREB 12668E). 
Adherent cells were maintained on tissue culture-treated polystyrene (Sarstedt, 
Newton, NC). Non-adherent cells (spheroids) were maintained for 72 h on Ultra-low 
Attachment (ULA) cultureware (Corning, Corning, NY) which is coated with a 
hydrophilic, neutrally charged hydrogel to prevent cell attachment. For spheroid re-
attachment assays, spheroids were removed from ULA cultureware and re-introduced to 
tissue culture-treated polystyrene for up to 72 h to allow for cell dispersion.  
 Quantitative RT-PCR 
Total RNA was isolated from primary adherent and spheroid EOC cells using 
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). RNA was isolated from reattached 
spheroids by first trypsinizing cells and spheroids from the tissue culture plastic. Purified 
RNA was quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). Reverse transcription was performed using total RNA isolated from 
independent patient samples (adherent and/or spheroid, treated and untreated) and 
Superscript II reverse transcriptase (Invitrogen) as per manufacturer’s instructions. PCR 
reactions were carried out using Brilliant SYBR Green QPCR Master Mix (Agilent 
Technologies/Stratagene) and a Stratagene Mx3000P machine with data exported to 
Microsoft Excel for analysis. Human-specific primers for CDH1 (E-cadherin), SNAI1 
(Snail), TWIST1, TWIST2, ZEB2, and VIM (Vimentin) were used (Sigma). GAPDH served 
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as an internal control for RNA input and quantification was performed using the ΔΔCt 
method [18]. 
 Western blot analysis 
Total cellular protein was isolated from primary adherent and spheroid EOC cells. 
Cells were washed once in cold phosphate-buffered saline (PBS), dissolved in lysis buffer 
[50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1mM EGTA, 1 mM 
sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1x protease inhibitor cocktail (Roche, 
Laval, Quebec, Canada)], clarified by centrifugation (20 min at 15,000g), and quantified 
by Bradford analysis (Bio-Rad Laboratories, Mississauga, Ontario, Canada). Nuclear 
fractions were isolated from primary adherent and spheroid EOC cells by washing cells in 
PBS, resuspending the cell pellet in a hypotonic lysis buffer [20 mM HEPES (pH 7.4), 1 
mM EGTA, 1 mM EDTA, 1 mM DTT] for 15 min on ice. Lysates were centrifuged, 
supernatant removed, and nuclear pellet washed twice with wash buffer [10 nM HEPES 
(pH 7.4), 10 mM KCl, 0.1 mM EGTA, 0.1 mM EDTA]. The washed nuclear pellet was 
dissolved in lysis buffer and clarified by centrifugation as described above for total cellular 
protein isolation. Forty to fifty micrograms of protein extract per lane were separated by 
SDS-PAGE in the presence of 1% β-mercaptoethanol using 8% or 10% gels. Proteins were 
then transferred to a polyvinylidene difluoride membrane (PVDF; Roche, Laval, Quebec, 
Canada), blocked with 5% BSA in Tris-buffered saline with Tween-20 [TBST; 10 mM 
Tris.HCl, pH 8.0, 150 mM NaCl, 0.1% Tween-20]. Membranes were washed in TBST and 
incubated (overnight, 4 ºC) with appropriate antibodies (1:1000 in 5% BSA/TBST). 
Immunoreactive bands were visualized by incubating (1 h, room temperature) with 
peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:10,000 in 1% skim milk/TBST; 
GE Healthcare) followed by exposure to enhanced chemiluminescence reagent 
(LuminataTM Forte, Millipore). 
 Antibodies and other reagents 
Antibodies against E-cadherin (#3195), Snail (#3879), β-Catenin (#9582P), 
Claudin-1 (#4933), Smad2 (#3122) and phospho-Smad2 (#3108S) were purchased from 
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Cell Signalling Technologies (Danvers, MA). Anti-human Lamin A+C antibody 
(MAB3211) was purchased from Millipore (Temecula, CA). Anti-actin antibody (A2066) 
and anti-α-tubulin (T5168) were purchased from Sigma (Mississauga, ON). Recombinant 
human TGFβ1 was purchased from Millipore (Temecula, CA) and prepared in distilled 
water, and used at a concentration of 10 ng/mL [9]. The TGFβ receptor I (TβRI) inhibitor, 
SB-431542, was purchased from Sigma and prepared in DMSO according to 
manufacturer’s instructions, and used at a concentration of 5 µM [19].   
 TGFβ signalling modulation  
To test TGFβ responsivity of primary EOC cells, adherent cells were treated with 
recombinant human TGFβ1 at 2, 24, and 72 h in reduced serum media (0.5% FBS). Cells 
were harvested for analysis at each time point and images were captured using a Leica DMI 
4000B inverted microscope.  Spheroids were treated with SB-431542 or dimethyl 
sulphoxide (DMSO) vehicle control at the time of initial seeding to ULA culture ware. 
Seventy-two hours later, spheroids were imaged and harvested for analysis. For spheroid 
re-attachment assays, native (untreated) spheroids were removed from ULA cultureware 
and re-introduced to tissue culture-treated polystyrene for 72 h to allow for cell dispersion. 
SB-431542 treatment or DMSO control was given at the time of re-attachment to tissue 
culture-treated plates and harvested 72 h later for analysis. 
 Spheroid re-attachment assay 
Macroscopically-visible spheroids (formed over 3 d) were transferred individually 
into single wells of 48-well tissue culture-treated polystyrene plates (12 replicates per 
treatment per EOC sample) and treated with DMSO or SB-431542 at the time of re-
attachment. Phase contrast images of each well were captured using Leica DMI 4000B 
inverted microscope at 24 h and dispersion area was quantified using ImageJ (NIH, 
Bethesda, MD), as described previously (Peart et al., 2012) Area of dispersion for each re-
attached spheroid was determined as total dispersion area minus spheroid (core) area at 24 
h. At 72 h, re-attached spheroids were fixed and stained using Hema-3 Stain kit (Fisher, 
Kalamazoo, MI). 
49 
 
 Transwell migration assay 
Primary EOC cells were seeded at 5 x 104 cells per well in 24-well ULA plates and 
treated with either DMSO or SB-431542 at the time of seeding. EOC spheroids were 
washed in PBS and transferred individually to 100 μL of reduced serum media (0.5% FBS) 
and added to the top chamber of a Transwell (6.5 mm in diameter; 8 µm pore size) 
(Costar®), with 600 μL of medium containing 10% FBS added to the bottom chamber of 
well. After a 12 h incubation, Transwell membranes were fixed and stained with Hema-3 
Stain kit and non-migrated cells on the upper side of the membrane were removed 
completely using a cotton swab. Migrated cells on the underside of the membrane were 
imaged with a Leica DMI 4000B inverted microscope. Images in five different fields per 
membrane were captured and cells were counted with ImageJ software. The mean number 
of migrated cells was determined for each Transwell.  
 Immunofluorescence 
Analysis of F-actin and β-catenin protein by fluorescent staining was performed on 
re-attached EOC spheroids seeded to glass coverslips and treated with SB-431542 or 
DMSO vehicle control at the time of spheroid re-attachment. After 72h, cells were fixed in 
a buffered 10% formalin solution and spheroid cores were removed leaving only the cells 
that have dispersed out of the spheroids attached onto the coverslips for analysis. Cells 
were washed with PBS and permeabilized with 0.1% Triton X-100 in PBS. Overnight 
incubation with anti-β-catenin antibody (1:500) was followed by one hour incubation with 
anti-rabbit fluorescein isothiocyanate-conjugated secondary antibody (1:500; Vector 
Laboratories) and subsequently a one hour stain with Alexa Fluor® 568-conjugated 
phalloidin (A12380, Invitrogen). Coverslips were mounted in VectaShield mounting 
medium (Vector Laboratories) containing 4′,6-diamidino-2-phenylindole (1:1000; Sigma, 
St. Louis, MO). Fluorescence images of mounted coverslips were captured using a Leica 
DMI 4000B inverted microscope. 
 Cell viability 
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Cells were seeded to either 24-well tissue culture plastic at a density of 1 x 104 per 
well to form adherent cultures, or ULA plates at a density of 5 x 104 per well to form 
spheroids. SB-431542 treatment was initiated at the time of seeding for cells in suspension, 
while cells under adherent conditions were given 12 h to adhere before commencing 
treatment. At 72 h post-treatment, spheroids were collected, pelleted and left in media (100 
μL), at which point CellTiter-Glo® reagent (Promega, Madison, WI) was added (1:1 v/v 
ratio). All samples were subjected to a freeze/thaw cycle prior to analysis. Approximately 
100 μL of the mixture was added to a white-walled 96-well microplate and luminescence 
signal was detected using a Wallac 1420 Victor 2 spectrophotometer (Perkin-Elmer, 
Waltham, MA) and normalized to vehicle-treated cells. Under adherent conditions, cells 
were kept in original 24-well plates and cell viability was assessed using alamarBlue® 
(Invitrogen, Burlington, ON) as per manufacturer's instructions. Briefly, medium was 
replaced with alamarBlue® reagent diluted 1:20 in complete medium, incubated for 4 h at 
37 °C in a humidified atmosphere of 95% air and 5% CO2, and then fluorescence was 
quantified using 560/590 nm excitation/emission filter settings.  
For measuring spheroid cell viability in the presence of carboplatin, spheroids were 
treated first with SB-431542 or DMSO for 72 h, followed by 100 µM carboplatin (LHSC 
Pharmacy, London, ON); CyQUANT® NF (Invitrogen, Burlington, ON) assays were 
performed 72 h later. Briefly, spheroids were collected and pelleted, and medium was 
removed. After a single freeze-thaw, spheroids were resuspended in 1X Hank’s balanced 
salt solution (HBSS), and 50 μL aliquots were dispensed into microplate wells. Fifty 
microlitres of 2X dye binding solution was added to each microplate well, and fluorescence 
signal was detected with the Wallac plate reader using 485/530 nm excitation/emission 
filter settings.  
 Statistical analysis  
Data were expressed as mean ± SEM. All statistical analyses were performed using 
a two-tailed Student’s t-test or one-way analysis of variation (ANOVA) with Tukey’s 
Multiple Comparison test. Significance levels were set at p < 0.05.  
2.3 Results 
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 EMT is induced during EOC spheroid formation 
To examine EMT in EOC ascites-derived cells, we followed the expression profile 
of the epithelial marker E-cadherin and mesenchymal markers known to repress E-cadherin 
(Snail, Twist1, Twist2, Zeb2) during spheroid formation and reattachment [20, 21]. We 
used an in vitro 3D culture system whereby primary ascites-derived human EOC cells are 
maintained in suspension on ultra-low attachment plates for 3 days,followed by re-
introduction to standard tissue culture-treated plates where they rapidly re-attach and 
disperse [22, 23]. Accordingly, we performed quantitative RT-PCR analysis on RNA 
isolated from several independent patient samples (n=6) that were grown in adherent, 
spheroid, and re-attached spheroid culture conditions. Compared to their matched adherent 
counterparts, primary EOC ascites cells were found to naturally undergo an EMT response 
during spheroid formation based on mRNA upregulation of SNAI1, TWIST1, TWIST2, 
ZEB2 and a coordinate down-regulation of CDH1 (Figure 2.1A). Of these mesenchymal 
markers, SNAI1 was the most robustly and consistently upregulated EMT marker in 
spheroids (11.7 - 42.5 fold increase). Several of these trends were strongly reversed upon 
EOC spheroid re-attachment (after 3 d re-attachment), as the mRNA levels of SNAI1, 
TWIST1, TWIST2, and ZEB2 return to levels comparable to those of matched adherent 
cells. Although CDH1 transcript levels begin to recover, they did not fully attain expression 
levels of original adherent cells in this model system.  
Western blotting was performed using protein lysates isolated from independent 
EOC ascites-derived human cells grown in the same culture conditions to verify the trends 
seen at the transcript level. In EOC spheroids, E-cadherin protein levels were down-
regulated and this was associated with a robust up-regulation of Snail. These effects started 
to reverse upon EOC spheroid re-attachment, although E-cadherin protein expression was 
not restored in most patient samples by 3 d after re-attachment (Figure 2.1B). Thus, RNA 
and protein expression data demonstrate EOC ascites-derived cells undergo endogenous 
EMT during spheroid formation, and this phenomenon is triggered to reverse upon 
spheroid re-attachment.  
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Figure 2.1: EMT is induced during EOC ascites cell spheroid formation and 
reversed upon re-attachment. 
(A) Quantitative RT-PCR analysis of CDH1, SNAI1, TWIST1, TWIST2, and ZEB2 mRNA 
in monolayer/adherent cells, spheroid cells, and 72 h re-attached spheroid cells using 
primary ascites-derived EOC patient samples (n=6). (B) Western blot analysis of E-
cadherin and Snail protein in adherent [A], spheroid [S] and 72 h re-attached spheroid 
samples [R] samples in primary ascites-derived EOC patient samples (n=7). Tubulin was 
used as a loading control.  
 
 
  
53 
 
 TGFβ signalling regulates EMT in primary ascites-derived EOC spheroids  
To address the potential mechanism by which EOC cells undergo endogenous EMT 
upon spheroid formation, we chose to assess the role of the TGFβ signalling pathway in 
mediating the pathobiological characteristics of EOC ascites spheroids. Previous 
microarray data from our lab [22] revealed increased TGFβ1 expression in EOC spheroids 
compared to adherent cells in five independent patient ascites samples (mean 4.36-fold, 
p<0.001). 
First, we tested the responsivity of primary EOC cells in adherent culture to TGFβ1 
treatment. In doing so, patient ascites samples (n=4) were treated with 10 ng/mL 
recombinant TGFβ1 ligand for 2, 24, and 72 h (Figure 2.2A) and quantitative RT-PCR 
analysis was performed. Treatment of adherent cells with TGFβ1 ligand resulted in a 
significant decrease of CDH1 mRNA at 24 h, but returned to near basal levels by 72 h. 
However, we observed significant increases in mesenchymal marker transcript levels for 
SNAI1, ZEB2, TWIST2, and VIM at 24 and 72 h. Moreover, transition of cells from a typical 
cobblestone epithelial morphology to a distinctly fibroblast-like phenotype was observed 
after 72 h of TGFβ1 treatment (Figure 2.2B), indicating induction of EMT and 
responsiveness of EOC ascites-derived cells to TGFβ. 
EMT was shown to be induced endogenously upon spheroid formation in primary 
ascites-derived EOC cells (Figure 2.1). Thus, we wanted to assess whether further 
treatment with exogenous TGFβ1 ligand would potentiate EMT phenotype induced in 
spheroids, and compare endogenous EMT induction in EOC spheroids to TGFβ1-induced 
EMT in adherent EOC cells. Quantitative RT-PCR analysis revealed no significant changes 
in CDH1, SNAI1, VIM, TWIST2, or ZEB2 mRNA levels in TGFβ1-treated EOC ascites 
spheroids relative to untreated spheroids (data not shown). Western blot analysis confirmed 
that treatment of spheroids with TGFβ1 does not further increase Snail protein levels 
(Figure 2.2C). Furthermore, there were higher levels of Snail protein in untreated spheroids 
compared to TGFβ1-treated EOC ascites cells indicating that spheroid formation alone 
may act as a potent inducer of EMT. We also observed that TGFβ1 treatment of adherent  
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Figure 2.2: TGFβ induces EMT in EOC ascites-derived cells but spheroid formation 
alone is a more potent inducer of EMT. 
(A) Quantitative RT-PCR analysis of CDH1, SNAI1, TWIST2, ZEB2 and VIM mRNA in 
control and TGFβ1-treated adherent EOC ascites-derived cells (n=4) at 2 h, 24 h, and 72 h 
(*, p<0.05 as determined by Student’s t-test). (B) TGFβ1 treatment of EOC ascites-derived 
cells induces transformation of epithelial cells towards a fibroblastic mesenchymal 
morphology. Representative image from EOC57 patient sample at 72 h post treatment 
(scale bar=200 µm). (C) Western blot analysis of E-cadherin, Claudin1, and Snail protein 
in adherent [A] and spheroid [S] samples treated with TGFβ1 or not in ascites-derived EOC 
patient samples (n=2). Tubulin was used as a loading control. Panels represent separate 
lanes from the same blot and same length of exposure. 
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cells results in sustained reduction in E-cadherin protein as compared with the slight 
recovery in CDH1 mRNA level at 72 h. 
Because we have observed increased TGFβ1 expression in EOC ascites-derived 
spheroids, we propose that endogenous TGFβ signalling activity regulates the natural 
induction of EMT observed in spheroids. In support of this, we have observed increased 
nuclear phosphorylated Smad2 and total Smad2 protein in spheroid cells as compared with 
adherent ascites cells (Figure 2.3). As such, we hypothesize that inhibiting TGFβ signalling 
in EOC ascites-derived cells in suspension will abrogate spheroid formation and induction 
of EMT. Inhibiting TGFβ signalling during spheroid formation using a TβRI small 
molecule inhibitor, SB-431542, efficiently blocked the EMT phenotype in spheroids as 
evidenced by a significant increase in CDH1 mRNA expression and a significant decrease 
in SNAI1, TWIST2, and ZEB2 mRNA expression (Figure 2.4A). Increased E-cadherin 
protein and decreased Snail protein expression were consistently seen in SB-431542-
treated spheroids compared to DMSO controls, indicating EMT is dramatically reduced in 
spheroids as a result of inhibiting TGFβ signalling (Figure 2.4B). In fact, SB-431542 
treatment resulted in spheroids that were much smaller in size and less cohesive than the 
compact control spheroids (Figure 2.4C), which resulted in decreased viability as compared 
with adherent cells (Figure 2.4D). We confirmed that SB-431542 treatment of adherent 
cells and spheroids resulted in blockade of TGFβ1-induced signalling by phospho-Smad2 
western blotting (Figure 2.5). In addition, SB-431542 treatment of adherent EOC ascites 
cells increases E-cadherin protein expression and promotes an exaggerated epithelial 
phenotype (data not shown). 
 TGFβ signalling inhibition during EOC spheroid re-attachment enhances the 
epithelial phenotype of dispersing cells and reduces cell motility  
A common feature of EMT in cancer is the enhanced capacity for malignant cells 
to migrate; and the capacity of EOC ascites cell spheroids to re-attach, grow, and disperse 
defines their ability to form secondary metastases [5]. Since inhibition of TGFβ signalling 
consistently blocks EMT and reduces cell-cell cohesion within spheroids, we sought to  
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Figure 2.3: Increased nuclear Smad2 indicating activated TGFβ signalling in 
spheroids.  
(A) Immunoblot analysis of phospho-Smad2 and total Smad2 on nuclear protein extracts 
isolated from EOC patient-derived ascites specimens cultured as adherent cells [A] or 
spheroids [S] (n=3). Lamin A/C was used as loading control. (B) Quantification of mean 
phospho-Smad2 and total Smad2 expression from the above immunoblots as normalized 
to Lamin A/C. 
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Figure 2.4: Inhibition of TGFβ signalling in spheroids blocks EMT and 
compromises EOC spheroid morphology. 
(A) Quantitative RT-PCR analysis of CDH1, SNAI1, TWIST2, and ZEB2 mRNA in 
control and SB-431542-treated spheroids (n=7; *, p<0.05 as determined by Student’s t-
test). (B) Western blot analysis of E-cadherin and Snail protein in spheroids formed from 
EOC ascites-derived patient samples (n=6). Actin was used as a loading control. (C) SB-
431542 treatment of EOC ascites-derived cells at the time of seeding to ULA forms 
smaller and less cohesive spheroids compared to DMSO controls. Representative image 
from EOC75 patient sample at 72 h post treatment (scale bar=500 µm). (D) Cell viability 
was determined using CellTiter-Glo® assay following 3 d of SB-431542 treatment, or 
DMSO control across EOC patient ascites samples (n=8) cultured as adherent cells and 
spheroids. Data is represented as mean ± SEM and Student’s t-test for statistical 
significance (***, p<0.001).    
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Figure 2.5: SB-431542 treatment of EOC adherent cells and spheroids blocks 
TGFβ1-induced signalling 
Immunoblot analysis of phospho-Smad2 and total Smad2 on whole-cell protein extracts 
isolated from EOC patient-derived ascites specimens (n=3).  EOC samples were serum-
starved overnight and pre-treated with SB-431542 for 30 min, and subsequently treated 
with 10 ng/mL TGFβ1 for 30 min.  Actin was used as loading control. 
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determine whether TGFβ signalling inhibition affects the ability of spheroids to re-attach 
and disperse. Thus, our first assessment was to quantify cell migration from SB-431542-
treated spheroids across a Transwell membrane. We observed that blockade of TGFβ 
signalling significantly reduced the ability of cells (n=9) to migrate out of spheroids across 
a Transwell membrane (Figure 2.6). Since we observed that SB-431542 treatment of 
spheroids reduces cell viability (Figure 2.3D), we could not attribute these Transwell assay 
results to migration only. Therefore, we also used spheroid re-attachment assays to quantify 
cell motility, where only viable spheroid cells will re-attach and disperse. Spheroids formed 
over 3 d from patient ascites samples (n=7) were plated individually for re-attachment 
using standard tissue culture- treated plates. Treatment with SB-431542, or DMSO control, 
was started at the time of seeding for re-attachment. Remarkably, we observed less-
cohesive spheroid cores within 24 h of SB-431542 treatment (Figure 2.7A). We also 
observed a significant decrease in cell dispersion area in SB-431542-treated spheroids 
compared with DMSO controls (Figure 2.7B). Since we demonstrated that SB-431542 
treatment did not affect ascites cell proliferation over 72 h (Figure 2.3D), this indicates that 
decreased dispersion from reattached spheroids is due to reduced cell motility via TGFβ 
signalling inhibition.  
Since inhibiting TGFβ signalling in re-attached spheroids decreased cell motility 
of dispersing cells, we postulated that this was due to an enhanced epithelial phenotype of 
dispersing cells. Indeed, EOC ascites-derived cell spheroids treated with SB-431542 during 
re-attachment yielded dispersing cells exhibiting an enhanced epithelial morphology 
compared with DMSO controls (Figure 2.7C). To assess the epithelial morphology of cells 
dispersing from re-attached spheroids further, we performed immunofluorescence staining 
for several cytological markers. Since it was difficult to obtain membrane-specific 
immunofluorescence staining of E-cadherin, we chose to assess β-catenin. β-catenin is an 
integral component of the protein complex in adherens junctions and binds to the E-
cadherin receptor intracellularly anchoring it to the actin cytoskeleton [24, 
25].  Furthermore, β-catenin protein expression was up-regulated in re-attached spheroids 
treated with SB-431542 by Western blot analysis (data not shown). Immunofluorescence  
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Figure 2.6: Inhibition of TGFβ signalling in spheroids decreases migration of cells 
across a Transwell.  
(A) SB-431542 treatment of EOC ascites-derived cells at the time of seeding to ULA and 
transfer of day 3 spheroids to Transwell inserts decreases cell migration as compared 
with DMSO-treated controls. Representative EOC154 patient sample showing fewer 
migrated cells in SB-431542 treated spheroids compared to DMSO controls (scale 
bar=100 µm). (B) Transwell cell migration of treated spheroids from patient-derived 
samples (n=9) quantified using ImageJ software and averaged amongst 5 different fields 
per image (*, p<0.05 as determined by Student’s t-test).  
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images showed enhanced plasma membrane localization of β-catenin in cells dispersing 
out of SB-431542 treated re-attached spheroids compared to DMSO controls (Figure 
2.7D). Moreover, phalloidin staining for F-actin showed reduced stress fiber formation in 
SB-431542 treated re-attached spheroids (Figure 2.7E), also indicative of an enhanced 
epithelial phenotype of dispersing cells. To further validate this at the molecular level, we 
performed quantitative RT-PCR analysis of RNA isolated from re-attached spheroids from 
several independent EOC patient ascites samples. Re-attached spheroids treated with SB-
431542 showed a significant up-regulation of CDH1 mRNA and this was associated with 
a down-regulation of SNAI1 (Figure 2.8A). This was further validated by western blot 
analysis which showed enhanced E-cadherin protein expression associated with reduced 
Snail protein expression (in 5 out of 6 re-attached EOCs) in SB-431542 treated re-attached 
spheroids compared to DMSO controls (Figure 2.8B).   
 SB-431542 treatment of spheroids potentiates carboplatin-induced cell death 
Platinum-based chemotherapy is the standard for first-line treatment of metastatic 
epithelial ovarian cancer, yet the majority of patients will eventually recur with platinum-
resistant disease [26]. Ovarian cancer spheroids are largely resistant to platinum treatment, 
likely due to their reduced proliferative state. To assess whether blocking TGFβ signalling 
can affect ovarian cancer spheroid sensitivity to platinum agents, we treated EOC spheroids 
with SB-431542 or vehicle control first, followed by treatment with carboplatin. We 
observed a dramatic reduction in viability in EOC ascites-derived cell spheroids that 
received a combined treatment of SB-431542 at day 0 followed by 72h carboplatin 
treatment at day 3, when compared to either SB-431542 treatment alone or a combined 
treatment of vehicle plus carboplatin (Figure 2.9A,B). These final results point to a critical 
role for TGFβ signalling in maintaining cell viability and achieving chemo-resistance in 
ascites-derived cell spheroid. 
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Figure 2.7: Inhibition of TGFβ signalling in re-attached spheroids decreases motility 
of dispersing cells and enhances their epithelial phenotype.  
(A) SB-431542 treatment of EOC spheroids started at the time of re-attachment to 
standard tissue culture plates disrupts the spheroid core and decreases cell dispersion 
area. Representative image from EOC154 patient sample at 24 h post treatment (scale 
bar=500 µm). (B) Dispersion area was  quantified using ImageJ software and averaged 
amongst 12 replicates per treatment condition (SB-431542 or DMSO control) for each 
EOC patient sample (n=7). Dispersion area was calculated 24 h after spheroids had been 
re-plated to standard tissue culture plastic (*, p<0.05 as determined by Student’s t-test). 
(C) SB-431542 treatment of spheroids started at the time of re-attachment to standard 
tissue culture plates disrupts EOC spheroid core and changes morphology of dispersing 
cells to a more cuboidal epithelial phenotype. Representative image from EOC154 patient 
sample that was Hema-3-stained at 72 h post treatment (scale bar=500 µm). (D,E) 
Immunofluorescence images of cells dispersing out of  SB-431542 treated re-attached 
spheroids shows enhanced β-catenin staining and reduced stress fiber formation (by 
rhodamine-phalloidin staining) compared to DMSO controls (scale bar=100 µm).  
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Figure 2.8: E-cadherin and Snail expression in SB-431542 treated re-attached 
spheroids  
(A) Quantitative RT-PCR analysis of CDH1 (E-cadherin) and SNAI1 (Snail) in SB-
431542-treated relative to DMSO-treated 24 h re-attached EOC spheroids (n=7; *, 
p<0.05 as determined by Student’s t-test). (B) Western blot analysis of E-cadherin and 
Snail protein in 24 h re-attached spheroids in EOC ascites-derived samples (n=7). Actin 
was used as a loading control. 
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Figure 2.9: TGFβ signalling in EOC ascites cells protects spheroids from platinum-
induced cell death  
(A) EOC ascites-derived cells (n=4) were treated with either DMSO or SB-431542 at the 
time of seeding to 24-well ULA cluster plate to form spheroids.  Three days later, 
spheroids were treated with carboplatin (100 M) for 72 h. Representative EOC209 
patient sample showing reduced spheroid formation potential (fewer spheroids, more 
single cells) with combined carboplatin and SB-431542 treatment (scale bar=1 mm). (B) 
Cell viability was determined using CyQUANT® NF assay. Data is represented as mean 
± SEM and one-way ANOVA with Tukey’s Multiple Comparison test (*, p<0.05; **, 
p<0.01; ***, p<0.001).  
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2.4 Discussion 
Spheroids have been postulated to act as important reservoirs of malignant EOC 
cells during spread throughout the peritoneal cavity in patients with late-stage disease [5, 
27] We had previously observed that epithelial ovarian cancer cells induce an endogenous 
EMT response upon spheroid formation [22]. Herein, we have confirmed this phenomenon 
among a larger array of ascites-derived specimens and implicated the role of TGFβ 
signalling in its regulation. We also observed the plasticity of this process, since the cells 
undergo MET to revert back to an epithelial phenotype upon spheroid reattachment to a 
substratum. Importantly, we identified that intact TGFβ signalling is required to elicit this 
EMT response in spheroids since the potent small molecule type I receptor inhibitor SB-
431542 blocks spheroid-induced EMT. SB-431542 treatment forces a more potent 
epithelial phenotype of dispersing cells from reattached spheroids, thereby reducing the 
spread of motile cells emanating from reattached spheroids. This also indicates that perhaps 
residual maintenance of TGFβ signalling acts to promote invasion and motility upon 
spheroid reattachment. Lastly, SB-431542 disrupts efficient EOC ascites cell spheroid 
formation and renders suspended cells more susceptible to carboplatin-mediated cell death. 
EMT has been observed in tumour cell spheroids and implicated in EOC metastasis, and 
we provide some essential insight into its regulation, as well as the therapeutic potential of 
targeting this important pathobiological process in late-stage EOC metastasis. 
Epithelial to mesenchymal transition is a widely accepted phenomenon that occurs 
in the malignant progression of most if not all human carcinomas [28]. Dynamics of EMT 
during EOC metastasis, particularly with its reversal, or MET, upon secondary tumour 
formation, has been discussed in the literature [9, 11]. For example, E-cadherin down-
regulation in ovarian cancer cells facilitates intraperitoneal spread [29], yet E-cadherin 
expression in metastases can be similar to the primary tumour [30]. We observed, however, 
that the level of E-cadherin expression upon spheroid re-attachment did not increase to 
initial levels completely, which may explain why secondary tumours oftentimes harbor low 
yet detectable E-cadherin in patients [31-33].  
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Differential E-cadherin expression supports the idea that switching between EMT 
and MET occurs during ovarian cancer metastasis and is important in disease progression. 
Our results provide further insight into the mechanism controlling this phenomenon of 
epithelial-mesenchymal plasticity within spheroids, which act as carriers of transiting 
metastatic cells in the peritoneal cavity. We demonstrate that the expression of classical 
EMT markers is rapidly induced during spheroid formation, yet the simple re-attachment 
to a substratum is sufficient to stimulate an MET cell phenotype. Our results imply that 
transcriptional repressors have immediate functions to induce EMT in spheroid formation 
and their reduction triggers the start of MET at reattachment since expression changes are 
rapid and sustained. It is peculiar that an EMT response would be induced in spheroids 
since these cells would not necessarily require a mesenchymal phenotype in these fairly 
static structures. However, one could envision that an EMT phenotype of spheroids primes 
the resident cells for invasive capabilities upon their subsequent reattachment [34]. On that 
note, E-cadherin is less immediately responsive particularly upon reattachment, perhaps 
indicating a delay to complete MET thereby facilitating spheroid cell motility and invasion. 
Induction of an EMT phenotype has been observed in other spheroid systems, usually in 
concert with stem-like cells [35, 36]; however, these reports have not described whether or 
not the EMT phenotype is reversible. It may be that this plasticity is a particularly unique 
characteristic of metastatic ovarian cancer, not unlike its almost exclusive mode of 
intraperitoneal spread which is unique when compared among other carcinomas. 
The induced expression of EMT markers in spheroids implies that their gene 
products may act to facilitate disease progression. Snail expression in ovarian cancer 
portends poor patient prognosis [37] and platinum resistance [38]. Ectopic Snail expression 
in ovarian cancer cell lines enhances oncogenic transformation properties and promotes 
tumour growth in mouse xenografts, yet similar manipulation of Slug expression failed to 
elicit the same effect [39]. Snail and Slug may have different functions in controlling EMT 
in ovarian cancer cells [40, 41], which supports our findings that SNAI2/Slug expression is 
not consistently altered during spheroid formation and reattachment (data not shown). This 
exemplifies the utility of using our experimentally-tractable in vitro system using patient-
derived cells not only to look at the dynamics of gene expression, but use it to dissect out 
the impact of these markers on spheroid cell biology. To this end, understanding Snail’s 
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function and its requirement on the EMT phenotype in spheroids, anoikis-resistance, and 
cell invasion upon spheroid reattachment will be important. In addition, it will be important 
to determine whether TGFβ signalling directly regulates the genes controlling EMT, e.g. 
SNAI1, TWIST1/2, in EOC spheroid cells, as well as other pathobiological processes that 
this metastasis-associated pathway may regulate during spheroid formation and 
transcoelomic metastasis. 
The TGFβ signalling pathway has been investigated for over 30 years in many 
human malignancies, including ovarian cancer [42]. Biologically-relevant concentrations 
of TGFβ ligands have been detected in malignant ascites from patients [43, 44]. Primary 
epithelial ovarian cancer cells possess an intact TGFβ signalling pathway, which can 
induce cytostasis upon its activation as long as CDKN2B encoding p15 is intact [44]. We 
showed previously that TGFβ signalling was present in spheroids [22]. This is consistent 
with TGFβ treatment regulating tissue transglutaminase 2 in ovarian cancer cells to 
promote EMT and spheroid formation [45]. In the present report, we have now uncovered 
a new function for active maintenance of endogenous TGFβ signalling in promoting the 
EMT phenotype of spheroids and their potential to reattach and spread. As such, TGFβ 
signalling may be essential to promote late-stage ovarian cancer progression, thus serving 
as a potential therapeutic target to reduce intraperitoneal spread and disease burden upon 
recurrence.  
Several attempts have been made in the past to test whether TGFβ signalling could 
be targeted with inhibitors in cancer treatment [46]. Perhaps the majority of these studies 
have looked at malignancies where metastasis had already occurred and thus the inhibitors 
may be less efficacious at this step of progression. Ovarian cancer represents an entirely 
different case, since after primary debulking and chemotherapy the majority of disease is 
reduced. The eventual recurrence of disease and the continual re-seeding of the peritoneal 
cavity with malignant cells imply that cyclic TGFβ signalling activity may be required to 
drive this process. Our results show that the underlying pathobiology of spheroid cells can 
be dramatically altered by treatment with the potent TGFβ type I receptor inhibitor SB-
431542. Most importantly, we also demonstrate that TGFβ signalling blockade reduces 
EOC spheroid cell viability in concert with carboplatin treatment. It would be intriguing to 
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test the numerous other TGFβ signalling inhibitors available [47], and apply them in an in 
vivo intraperitoneal ovarian cancer metastasis model to offer further supportive evidence 
that the therapeutic potential of targeting TGFβ signalling can be re-evaluated in ovarian 
cancer. 
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Table S2.1: Summary of ovarian cancer patient clinical data. 
Sample Age Histological Subtype Grade Stage 
EOC57 46 Serous High IIIC 
EOC65 67 Serous High IIIC 
EOC75 77 Serous High IIIC 
EOC80 49 Serous High III 
EOC82 44 Serous High IIIC 
EOC98 31 Serous High IIIC 
EOC117† 60 Clear cell High IIIC 
EOC118 57 Serous High IIIC 
EOC121 78 Serous High IIIC 
EOC140 76 Serous High IIIC 
EOC148 67 Serous High IC 
EOC154 66 Serous High IIIC 
EOC202 80 Serous  n.a. IIC 
EOC207* 65 Serous High n.a. 
EOC209* 52 Serous High n.a. 
EOC238 70 Serous High  n.a. 
EOC240 47 Serous  High IIIC 
EOC241† 60 Serous  Low n.a. 
EOC242 75 Serous High IIIC 
EOC243 56 Serous High IIIC 
EOC253* 63 Serous High n.a. 
EOC261 61 Serous High IIIC 
EOC262 73 Serous High IIIC 
EOC281* 60 Serous High IIIC 
 
†: One sample was from a patient with low-grade serous histology (EOC241) and one 
sample from a patient with clear cell histology (EOC117); the results using these two 
samples did not differ from the high-grade serous histologies. 
*: These four ascites samples are from patients who had been treated with chemotherapy 
prior to collection for experimentation; the results using these four samples did not differ 
from chemotherapy-naïve samples. 
n.a.: not available 
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Chapter 3 
3 SNAIL ENHANCES THE METASTATIC POTENTIAL OF OVARIAN 
CANCER SPHEROIDS 
3.1 Introduction 
Ovarian cancer is the most lethal of the gynecologic malignancies in the developed 
world, existing predominantly as epithelial ovarian cancer (EOC) [1, 2]. Early detection 
significantly enhances survival of EOC patients; however, the overall prognosis remains 
poor since most patients (>75%) are initially diagnosed when the tumour has already 
metastasized beyond the primary site [3]. An accumulation of malignant fluid, or ascites, 
is commonly seen in the peritoneal cavity of these patients. Malignant EOC cells exist and 
survive in the ascites fluid as spheroid-like structures. EOC spheroids adhere and invade 
the peritoneum to seed metastatic tumour growth and are resistant to standard 
chemotherapeutics, providing unique therapeutic challenges for the treatment of EOC [4, 
5].  
Epithelial-mesenchymal transition (EMT) is an important mechanism responsible 
for the invasion and metastasis of many epithelial cancers [6]. EMT refers to the conversion 
of epithelial cells to fibroblast-like cells, and characterized by the loss of epithelial markers 
and acquisition of mesenchymal ones, and the enhancement of cell motility and invasion 
[7, 8]. In fact, EOC cells have the capacity to switch between epithelial and mesenchymal 
states during metastasis [4, 9].We have discovered that EOC patient ascites-derived cells 
naturally undergo a robust EMT response by simply aggregating into spheroids - the 
conduits of metastasis within ascites fluid [10]. Spheroid-induced EMT was characterized 
by the highest upregulation of Snail (SNAI1) amongst other factors and this was dependent 
on endogenous transforming growth factor-beta (TGFβ) signalling, which the most widely-
studied initiator of EMT [11]. Indeed, we demonstrated that inhibiting endogenous TGFβ 
signalling in EOC cells ablates Snail expression and potently blocks EMT in EOC ascites-
derived spheroid cells, compromising spheroid formation, viability, and cell motility and 
migration.  
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Snail serves a pivotal role in repressing epithelial genes during EMT including 
CDH1, which encodes E-cadherin [12]. Snail expression is a common indicator of poor 
prognosis in metastatic cancer, including ovarian, since tumours with elevated Snail 
expression are disproportionately more difficult to eradicate by current therapeutic 
treatments [12, 13]. In fact, Snail expression is positively correlated with the stage of 
human ovarian carcinoma, and it is significantly higher in metastatic lesions as compared 
with primary tumours [14]. Surprisingly, there is limited evidence regarding the functional 
role of Snail in EOC progression, especially in the context of three-dimensional spheroid 
pathobiology, a clinically-relevant metastasis model system [15]. Since we observed Snail 
to be the most highly upregulated mesenchymal marker induced upon spheroid formation 
and robustly reduced by blocking endogenous TGFβ signalling in EOC ascites-derived 
cells [10], we propose that Snail is the key downstream effector of TGFβ signalling in 
spheroid-induced EMT and is important for the survival and metastatic behaviour of EOC 
spheroids. 
In this study, we explored Snail function in EOC spheroids using patient ascites-
derived cells and ovarian cancer cell lines. Snail expression facilitated spheroid cell 
viability, and it was critical for the adhesion, migration, and invasion potential of ovarian 
cancer spheroid cells. Furthermore, using an ex ovo chickCAM assay, ectopic Snail 
expression in Hey ovarian cancer cell spheroids enhanced tumour-forming potential, 
invasion, and metastasis. These results expand our understanding of the function of Snail 
in ovarian cancer progression, highlighting the therapeutic potential for targeting Snail and 
the EMT process in late-stage ovarian cancer. 
3.2 Materials and Methods 
 Cell culture 
Ascites obtained from ovarian cancer patients (diagnosed with high-grade serous 
EOC) was used to generate primary cell cultures as described previously [16]. Ascites was 
mixed 1:1 with growth medium [MCDB105 (Sigma, St. Louis, MO) / M199 (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Wisent, St. Bruno, 
Quebec, Canada) and 50 µg/mL penicillin-streptomycin. Experiments were performed 
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using cells between passages 3 and 5. All patient-derived cells were used in accordance 
with institutional human research ethics board approval (UWO HSREB 12668E). The 
iOvCa147-E2 cell line was generated from an ascites sample (EOC147) collected at our 
centre. OVCAR3 and OVCAR8 (purchased from ATCC, Manassas, VA) and Hey (gift 
from G. Mills, MD Anderson) cells were cultured in Dulbecco’s Modified Eagle 
medium/F12 (Wisent) with 10% FBS (Wisent).  Cells were grown in a 37ᵒC humidified 
atmosphere of 95% air and 5% CO2. Cell lines were authenticated by short tandem repeat 
analysis (Genetic Analysis Facility, The Hospital for Sick Children, Toronto, ON, Canada). 
Adherent cells were maintained on tissue culture-treated polystyrene (Sarstedt, 
Newton, NC). Non-adherent cells (spheroids) were maintained for 72 h on Ultra-Low 
Attachment (ULA) cultureware (Corning, Corning, NY). For spheroid re-attachment 
assays, spheroids were removed from ULA cultureware and re-introduced to tissue culture-
treated polystyrene for up to 72 h. 
 SNAI1 (Snail) knockdown  
Cells were plated at a density of 3 × 105 cells per 35 mm well in antibiotic-free 
media, and transfections were performed the next day using DharmaFECT1 as per 
manufacturer’s protocol (Dharmacon; GE Healthcare, Mississauga, ON). Briefly, 1 μL of 
DharmaFECT1 was combined with 10 nM siRNA in 1 mL of media and incubated for 20 
min, then added to each well. Media was replaced at 24 h with antibiotic-free growth media. 
Cells were incubated 72 h following transfection, then cells were trypsinized and seeded 
for adherent and spheroid cell viability assays. Human SNAI1 siGENOME SMARTpool 
(M-010847-00) and non-targeting (control) siRNA was obtained from Dharmacon. 
Western blot analysis was performed on adherent cell lysates at 72 h post-transfection and 
72 h post-seeding to ULA plates for spheroid lysates. 
 Ectopic SNAI1 expression via retroviral transduction  
Human Embryonic Kidney (HEK) 293T cells were seeded at 5 x 105 cells per 60 
mm plate and maintained in DMEM with 5% FBS. Transfections were performed at 24 h 
using Lipofectamine® 2000 Reagent (Invitrogen) according to manufacturer’s instructions. 
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Plasmids pMDG, pPSI, (gift from Dr. Mellissa Mann, Western U.) and pBABEpuro-
SNAIL (Addgene) or pBABEpuro (Addgene) were co-transfected into HEK293T cells. 
Hey cells (approximately 80% confluent) were pre-treated for 45 min with 4 g/mL 
polybrene (Sigma) prior to retroviral infection. Transfected HEK293T supernatant was 
clarified with a 0.45 micron syringe filter, diluted 1:1 in RPMI/5% FBS, and applied to 
Hey cells. At confluence, infected Hey cells were expanded and selected using 2 g/mL 
puromycin to generate individual clones and populations. 
 Western blot analysis 
Adherent and spheroid cells were washed once in cold phosphate-buffered saline 
(PBS), dissolved in lysis buffer [50 mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 
mM MgCl2, 1mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 
10 mM NaF, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1x 
protease inhibitor cocktail (Roche, Laval, Quebec, Canada)], clarified by centrifugation 
(20 min at 15,000g), and quantified by Bradford analysis (Bio-Rad Laboratories, 
Mississauga, Ontario, Canada). Western blotting of protein lysates was performed as 
described previously [10]. Immunoreactive proteins were detected using enhanced 
chemiluminescence reagent (LuminataTM Forte, Millipore) and imaged with the ChemiDoc 
MP System (BioRad, Mississauga, ON).  Anti-Snail antibody (#3879) was purchased from 
Cell Signalling Technologies (Danvers, MA). Anti-actin antibody (A2066) was purchased 
from Sigma (Mississauga, ON).  
 Spheroid re-attachment assay 
Macroscopically-visible spheroids formed from siNT or siSNAI1-transfected EOC 
ascites cells (n=7) after three days in suspension culture were transferred individually into 
wells of 48-well tissue culture-treated plates (minimum n=12 per sample). Re-attached 
spheroids were fixed and stained at 72 h (Hema-3 Stain kit; Fisher, Kalamazoo, MI), and 
images were captured using Leica DMI 4000B inverted microscope to quantify dispersion 
area (total area minus spheroid core) using ImageJ (NIH, Bethesda, MD). 
 Cell viability 
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Cells were seeded to either 24-well tissue culture plastic (1 x 104 cells/well) for 
adherent cultures, or ULA plates (5 x 104 cells/well) for spheroids. For siSNAI1 
experiments, spheroids were collected 72 h after seeding to ULA (6 days post-transfection), 
pelleted and left in media (100 μL), at which point CellTiter-Glo® reagent (Promega, 
Madison, WI) was added (1:1 v/v ratio). All samples were subjected to a freeze/thaw cycle 
prior to analysis of luminescence signal detected using a Wallac 1420 Victor 2 
spectrophotometer (Perkin-Elmer, Waltham, MA). Under adherent conditions, cells were 
kept in original 24-well plates for 3 days and cell viability was assessed using alamarBlue® 
(Invitrogen, Burlington, ON) as per manufacturer's instructions. Fluorescence was 
quantified at 4 h using 560/590 nm excitation/emission filter settings on the Wallac 
spectrophotometer.  
For measuring viability in HeyBABE and HeySNAIL spheroid cells, CyQUANT® 
NF (Invitrogen, Burlington, ON) assays were performed after 72 h in suspension culture. 
Briefly, spheroids were collected and pelleted, and medium was removed. After a single 
freeze-thaw, spheroids were resuspended in 1X Hank’s balanced salt solution (HBSS), and 
50 μL aliquots were mixed 1:1 with 2X dye binding solution in each microplate well; 
fluorescence was detected with the Wallac spectrophotometer using 485/530 nm filter 
settings.  
 Immunofluorescence 
Confluent HeyBABE and HeySNAIL cells on glass coverslips were fixed in 
buffered 10% formalin, washed with PBS, and permeabilized with 0.1% Triton X-
100/PBS. Overnight incubation with anti-Vimentin antibody (#5741, Cell signalling), or 
anti-Snail antibody (1:500 each) was followed by one-hour incubation with anti-rabbit 
fluorescein isothiocyanate-conjugated secondary antibody (1:500; Vector Laboratories) 
and a one-hour stain with Alexa Fluor® 568-conjugated phalloidin (A12380, Invitrogen). 
Coverslips were mounted in VectaShield mounting medium (Vector Laboratories) 
containing 4′,6-diamidino-2-phenylindole (1:1000; Sigma, St. Louis, MO). Fluorescence 
images were captured using an Olympus AX70 upright microscope and ImagePro image 
capture software. 
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 Colony forming soft agar assay 
HeyBABE and HeySNAIL cells were suspended in media (supplemented with 20% 
FBS) and mixed 1:1 with 1% agarose prior to seeding agarose pre-coated 6-well plates (at 
2.5 x 104 cells/well). Media (with 10% FBS) was added to each well, and replaced every 
48 h for 2 weeks. Images were captured (six fields of view per well) using a Leica DMI 
4000B inverted microscope, and colonies were counted using ImageJ software.  
 Scratch-wound assay 
Confluent adherent cultures of HeyBABE and HeySNAIL cells were scratched 
with a P1000 tip and washed twice with PBS to remove detached cells, and media was 
replaced. Images were captured using a Leica DMI 4000B inverted microscope at initiation 
(0 h) and at 4 and 10 h post-wounding, and cell motility was quantified using ImageJ 
software.  
 Adhesion assay 
HeyBABE and HeySNAIL spheroids were transferred to tissue culture plastic, 
collagen-coated plates (354402, Corning), or fibronectin-coated plates (152034, Thermo 
Scientific Nalgene), and incubated for 30 min. Re-attached spheroids were fixed and 
HEMA3-stained after 30 min, and quantified. Representative images were captured using 
using a Zeiss Axiozoom.V16 stereo macroscope and ZEN software (ZEISS). 
 Transwell migration and invasion assay 
EOC ascites cells were formed from siNT or siSNAI1 transfection cells seeded at 5 
x 104 cells per well in 24-well ULA plates. Spheroids formed from HeyBABE and 
HeySNAIL cells were seeded at 2.5 x 104 cells per well in 24-well ULA plates. After 3 
days, PBS-washed spheroids were transferred individually to 100 μL of reduced serum 
media (0.5% FBS) and added to the top chamber of a Transwell (6.5 mm in diameter; 8 µm 
pore size) (Costar®), with 600 μL of medium containing 10% FBS in the bottom chamber. 
Transwell membranes were fixed and stained with Hema-3 Stain kit at 12 h and non-
migrated cells were removed using a cotton swab. Migrated cells were imaged with a Leica 
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DMI 4000B inverted microscope (five fields/membrane) and counted with ImageJ 
software. 
Transwell membranes were coated with either rat tail collagen I (A1048301, 
Gibco® Life Technologies) or human fibronectin (PHE0023, Gibco® Life Technologies) 
matrices.  Briefly, stock solutions for each were diluted to 50 µg/mL, and 50 µL was added 
to the apical chamber and incubated for 2 h at 37ᵒC. The remaining solution was aspirated 
dried for 30 min, then media was added to the apical and basolateral compartments for 30 
min at 37ᵒC. HeyBABE and HeySNAIL spheroid cell invasion was performed as described 
above in migration assays but were allowed to incubate for 18 h.  
 Chick embryo chorioallantoic membrane (CAM) assay 
Adherent HeySNAIL and HeyBABE cells were labelled with Molecular ProbesTM 
Lipophilic Tracer DiO at 1:500 for 2 h.  Cells were washed twice with PBS, trypsinized, 
pelleted, and re-suspended in fresh media (supplemented with 10% FBS) for subsequent 
seeding into 6-well ULA plates at 5 x 104 cells per well to form spheroids.  Three days 
later, spheroids were used for chick-CAM assays which were prepared as previously 
described [17-21]. Using embryonic day-10 chicks, 6 DiO-labelled spheroids in 20 µL of 
serum-free media were implanted between branching vessels on the CAM and incubated 
in a humidified 37°C stationary hatcher for 7 d. Brightfield and fluorescent images of 
tumour were captured using the Zeiss Axiozoom.V16 stereo microscope and ZEN 
software. The total number of chicks were n=48 for HeySNAIL and n=52 for HeyBABE 
spheroid over 6 independent experiments.  
Tumours were harvested for histology (H&E and human anti-Ki-67 
immunostaining) and slides were imaged using Aperio ScanScope slide scanner (Leica 
Biosystems). Livers were harvested and genomic DNA was extracted using a QIAamp Fast 
DNA Stool mini kit (51604, Qiagen), and 15 ng of DNA was used for quantitative PCR 
using Brilliant SYBR Green QPCR Master Mix (Agilent Technologies/Stratagene) and a 
QuantStudio3 thermocycler (Thermo Fisher Scientific). Human-specific primers for Alu 
sequences [forward: 5’- ACG CCT GTA ATC CCA GCA CTT – 3’; reverse: 5’- TCG 
CCC AGG CTG GAG TGC A -3’] (Sigma) were used to detect tumour cells and chicken 
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Gapdh [forward: 5’- AGA GAA AGG TCG CCT GGT GGA TCG -3’; reverse: 5’- GGT 
GAG GAC AAG CAG TGA GGA ACG -3’] served as an internal control for RNA input 
with quantification using the 2ΔCt method [22]. 
 Statistical analysis 
Data were expressed as mean ± SEM. Statistical analyses were performed using a 
two-tailed Student’s t-test or one-way analysis of variation (ANOVA) with Tukey’s 
Multiple Comparison test.  
3.3 Results 
 SNAI1 knockdown in EOC ascites-derived cells reduces spheroid cell 
migration  
We have demonstrated previously that Snail is consistently the most up-regulated 
EMT marker in EOC spheroids [10]. In addition, among the classical transcriptional 
repressors known to be involved in mediating EMT in cancer, SNAI1 (encoding Snail) 
possesses the most frequent copy-number alterations (as evidenced by amplifications and 
overexpression) among serous ovarian carcinomas in the Cancer Genome Atlas dataset and 
the 50 established cell lines from the Cancer Cell Line Encyclopedia dataset [23, 24] 
(Figure 3.1). It should also be noted, that there are no deletions in SNAI1 identified in either 
of these two large datasets, indicating a potential selective pressure to retain Snail 
expression and function in ovarian cancer.  
To initiate our analysis of Snail function in EOC spheroids, we utilized an siRNA-
mediated knockdown approach to reduce Snail expression. First, we assayed for the 
expression of Snail protein in several cell lines cultured as adherent cells or spheroids. 
Consistent with our previous observations in EOC ascites-derived cells [10], we observed 
Snail up-regulation in spheroids generated from Ovcar8, Ovcar3, and iOvCa147-E2 
ovarian cancer cell lines (Figure 3.2A). Using these cell lines, transient Snail knockdown 
was performed in adherent culture and spheroids (Figure 3.2B). In day-3 spheroids, 
siSNAI1-transfected cells formed smaller, loosely-aggregated spheroids when compared  
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Figure 3.1: Oncoprint analysis of SNAI1 and its EMT-related transcriptional 
repressor genes in high-grade serous ovarian carcinoma. 
Putative copy number alterations from GISTIC, gene mutation, and mRNA expression 
(RNA seq V2 RSEM) for SNAI1, SNAI2, TWIST1, TWIST2, ZEB1 and ZEB2 were 
assessed in ovarian serous carcinomas using cBioPortal (TCGA provisional dataset, 597 
cases). Only samples with alterations are shown. 
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with siNT controls in Ovcar3 and iOvCa147-E2 cell lines (Figure 3.2C). Snail knockdown 
did not affect the ability of Ovcar8 cells to form multicellular aggregates. Reduced Snail 
expression had no effect on the viability of adherent cells in all three cell lines, but resulted 
in decreased cell viability in Ovcar3 and iOvCa147-E2 spheroids (Figure 3.2D), which 
correlated with spheroid morphology. Thus, Snail may be necessary for normal spheroid 
formation and cell viability in these structures, at least in a subset of ovarian cancer cell 
lines.  
Transient SNAI1 knockdown in several EOC ascites-derived cells (n=4) was 
achieved in adherent monolayer culture, and sustained for 3 days in suspension culture 
during spheroid formation (Figure 3.3A). Snail knockdown had variable effects on EOC 
spheroid formation: either siSNAI1 had no effect on spheroid structure (data not shown), 
or siSNAI1-transfection yielded loosely-aggregated spheroids as compared with siNT 
controls (Figure 3.3B). Snail knockdown had no effect on the viability of adherent EOC 
ascites cells, but caused a significant yet modest reduction in cell viability of EOC 
spheroids among all samples tested (Figure 3.3C). These data indicate that Snail up-
regulation in EOC ascites-derived spheroids promotes an EMT phenotype, but may not be 
a critical factor for maintaining cell viability in these structures. 
We previously demonstrated that inhibition of endogenous TGFβ signalling and 
resultant EMT in EOC spheroids decreases cell motility of dispersing cells upon spheroid 
re-attachment, as well as spheroid cell migration [10].  Herein, we sought to investigate 
whether Snail specifically controls cell motility and migration during EOC spheroid re-
attachment and dispersion. To assess cell motility, spheroids formed from EOC ascites-
derived cells transfected with siSNAI1 or siNT control were seeded individually for re-
attachment to standard tissue culture plastic (n=7).  At 72 h, no differences in dispersion 
area were observed between siNT and siSNAI1 re-attached spheroids (Figure 3.4). 
However, we observed that SNAI1 knockdown in EOC ascites-derived spheroids 
significantly reduced cell migration in Transwell migration assays as compared with siNT 
controls (Figure 3.5D and E). Thus, up-regulated Snail expression in EOC ascites-derived 
spheroids is required for promoting cell migration during re-attachment.  
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Figure 3.2: SNAI1 knockdown in Ovcar3 and iOvCa147-E2 ovarian cancer cell lines 
reduces spheroid cell viability. 
(A) Ovcar8, Ovcar3, and iOvCa147-E2 cell lines express increased Snail protein in 
spheroids compared with adherent cells as determined by Western blotting. Actin served 
as a loading control. (B) SNAI1 knockdown in transfected adherent and spheroid ovarian 
cancer cell lines; siNT served as a negative control and actin was used as a loading 
control. (C) SNAI1 knockdown in Ovcar3 and iOvCa147-E2 cells reduces spheroid 
formation as evidenced by increased cell debris; no effect was observed with Ovcar8 
spheroids.  (D) Cell viability in monolayer cells and spheroids using alamarBlue assay 
and CellTiter-Glo, respectively (**, p<0.01; ***, p<0.001 as determined by Student’s t-
test). 
 
  
87 
 
 
Figure 3.3: SNAI1 knockdown in EOC ascites-derived cells reduces spheroid cell 
viability and migration.  
(A) Transient SNAI1 knockdown in monolayer and spheroid cells using four EOC patient 
ascites-derived samples with control non-targeted siRNA (siNT) as determined by 
Western blotting. Actin served as a loading control. (B) Phase contrast images of 
spheroids from representative ascites-derived cell transfections demonstrating variable 
SNAI1 knockdown effects on spheroid structure. (C) Cell viability of siRNA-transfected 
EOC ascites-derived monolayer cells and spheroids using alamarBlue assay and 
CellTiter-Glo, respectively. (n=4; *, p<0.05 as determined by Student’s t-test). (D) 
Spheroids formed from EOC ascites-derived cells transfected with siSNAI1 or siNT 
control were seeded to Transwell inserts with migration towards 10% FBS for 12 h; 
representative images of migrated stained cells are shown. (E) EOC ascites-derived 
siSNAI1-transfected spheroid cells have decreased cell migration as quantified among 
five fields per image (n=3; ***, p<0.001 as determined by Student’s t-test). 
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Figure 3.4: SNAI1 knockdown in EOC ascites-derived cells does not affect spheroid 
re-attachment. 
(A) Spheroids formed from EOC ascites-derived cells transfected with siSNAI1 or siNT 
control were seeded individually for reattachment to tissue culture plastic; representative 
images are shown. (B) Area of cell dispersion was quantified at 72 h post-reattachment 
using ImageJ.  No difference in dispersion area was observed between siSNAI1 and siNT 
reattached spheroids (n=7; Student’s t-test).  
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  Ectopic Snail expression in Hey cells induces a robust mesenchymal 
phenotype 
Assessment of Snail expression in several ovarian cancer cell lines showed that Hey 
cells lack Snail protein expression and it is not induced in spheroids (Figure 3.5A). Thus, 
we ectopically expressed Snail in Hey cells to examine the functional consequences of 
ectopic expression.  Retroviral transduction was followed to generate populations 
(HeySNAIL) as well as several individual clones (HeySNAIL-1, -2, -3, and -4); control 
Hey cell populations (HeyBABE) and as well as clones (HeyBABE-1) (Figure 3.5B; Figure 
3.6). 
Ectopic Snail expression in Hey cells induced a robust and sustained mesenchymal 
phenotype in adherent HeySNAIL populations and clones as compared with control cells 
(Figure 3.5C and D). Snail-expressing Hey cells had a more fibroblastic spindle-shaped 
morphology (Figure 3.5C) with intense stress fiber formation and enhanced vimentin 
staining (Figure 3.5D), indicating an induced mesenchymal phenotype as compared with 
controls.  
To further characterize the malignant potential of Snail-expressing Hey cells, we 
assayed for cell proliferation, anchorage-independent growth and cell motility. HeySNAIL 
populations and clones had reduced cell proliferation relative to control cells in adherent 
culture (Figure 3.7A). To assess anchorage-independent growth, HeySNAIL cells and 
controls were seeded in soft agar; over 14 d, Snail expression enhanced Hey cells colony 
formation as compared with control cells (Figure 3.7B). Scratch wound assays, however, 
revealed no significant differences in cell motility of Hey cells with or without Snail 
expression (Figure 3.7C and D). 
 HeySNAIL spheroid cells have enhanced adhesion, invasion and migration 
potential  
Since we have observed disrupted spheroid formation and reduced EOC spheroid 
cell migration by TGFβ signalling inhibition [10] and Snail knockdown (Figure 3.3D and 
E), we assessed spheroid formation and migration capacity of HeySNAIL cells compared   
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Figure 3.5: Ectopic Snail expression in Hey cells induces a robust mesenchymal 
phenotype. 
(A) Hey cells do not express endogenous Snail protein whether in adherent or spheroid 
culture. (B) Snail protein expression as determined by Western blotting in retrovirally-
transduced Hey cells. HeySNAIL and HeyBABE controls represent mixed populations, 
whereas HeySNAIL-1, -2, -3 and -4 and HeyBABE-1 represent individual clones. Actin 
was used as a loading control. (C) Brightfield images of Hema3-stained HeySNAIL cells 
and clones exhibit an enhanced mesenchymal or spindle-shaped morphology as compared 
with HeyBABE control cells. (D) Fluorescence images of HeySNAIL-2, -3 and -4 cell 
clones show enhanced stress fiber formation (rhodamine-conjugated phalloidin) and 
vimentin expression as compared with HeyBABE control cells. Scale bar=100µM 
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Figure 3.6: Immunofluorescence microscopy of Snail in HeySNAIL cell populations 
and clones. 
Nuclear Snail immune-staining is present in HeySNAIL cell populations and clones, and 
absent in HeyBABE population cells.  
  
94 
 
 
 
Figure 3.7: HeySNAIL cells have reduced proliferation but enhanced growth in soft 
agar. 
(A) Proliferation of HeyBABE and HeySNAIL cell populations and clones was measured 
by alamarBlue assay at days 1, 3, 5, and 7 after seeding. (B) Colonies of HeyBABE and 
HeySNAIL cells grown in soft agar over 14 days were imaged and quantified; 
representative images are shown. (C) Scratch wound assays were performed using 
HeyBABE and HeySNAIL cell populations and clones and cell motility was measured at 
4 and 10 h post-wounding. (D) Representative phase contrast images of scratch wound 
assays using HeyBABE-1 and HeySNAIL cell populations. Images were captured at 
initiation of the wound (0 h) and at 4 and 10 h post-wounding. 
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Figure 3.8: HeySNAIL spheroid cells have enhanced Transwell migration. 
(A) HeyBABE and HeySNAIL cell populations and clones were seeded into 24-well 
ULA plates. Representative images were captured at day-3 in suspension. (B) Spheroid 
cell viability was measured using CyQUANT assay. (C) Spheroids formed from 
HeyBABE and HeySNAIL cell populations and clones were seeded to Transwell inserts 
containing 0.5% FBS and allowed to attach and migrate towards 10% FBS for 12 h; 
representative images of migrated stained cells are shown. (D) Number of migrated cells 
was quantified and averaged amongst five different fields per sample (*, p<0.05 as 
determined by Student’s t-test). 
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with control cells lacking Snail expression.  Snail-expressing Hey cells formed spheroids 
of similar morphology as compared with controls (Figure 3.8A). Indeed, there were no 
significant differences in cell viability among spheroids formed from all HeySNAIL cells 
and controls (Figure 3.8B). Although there were no effects on spheroid formation, 
HeySNAIL spheroids showed significantly enhanced cell migration capacity through 
Transwell membranes as compared with control spheroids (Figure 3.8C and D).   
These results were further explored by adhesion and invasion assays performed 
using collagen and fibronectin matrices, which are established substrates for EOC cell 
attachment [25, 26]. Hey spheroids expressing Snail displayed significantly enhanced 
adhesion to standard tissue-culture plastic (Figure 3.9A and Figure 3.10A) and fibronectin-
coated wells (Figure 3.9B and Figure 3.10B) as compared with control spheroids. There 
was a trend towards increased cell adhesion to collagen for HeySNAIL spheroids (Figure 
3.9C and Figure 3.10C). In addition, Snail-expressing Hey spheroids exhibited enhanced 
invasion through both collagen (Figure 3.9D and E; Figure 3.11A) and fibronectin (Figure 
3.9F and G; Figure 3.11B) matrices.  
 HeySNAIL spheroids have enhanced tumour-forming potential in an ex ovo 
chick CAM assay 
We wished to rapidly assess whether ectopic Snail expression in Hey spheroid cells 
would enhance their ability to attach and form secondary tumours akin to ovarian cancer 
trans-coelomic metastasis mechanisms. To this end, we investigated spheroid attachment 
and tumour formation using an ex ovo chick embryo chorioallantoic membrane (CAM) 
assay. Using the ex ovo chick CAM as a xenograft model facilitates the rapid and direct 
visualization of tumour growth over a duration of only 7 d [17, 18]. HeySNAIL and control 
cells were first DiO-labelled prior to spheroid formation to track tumour cell growth and 
monitor invasion on the CAM surface; we confirmed DiO-label retention in spheroids over 
7 d in culture (Figure 3.12A). After 7 d post-implantation of spheroids on the CAM (6 
spheroids were xenografted in a single location per embryo), we observed a significant 
increase in xenograft tumour size generated by HeySNAIL spheroids (n=48 embryos) as  
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Figure 3.9: HeySNAIL spheroid cells display enhanced adhesion and invasion. 
(A, B, C) Spheroids formed from HeyBABE and HeySNAIL cell populations and clones 
were transferred to standard tissue culture plastic plates (A), fibronectin-coated plates 
(B), or collagen-coated plates (C). Re-attached spheroids were quantified at 30 min post-
reattachment. (D, E) Spheroids formed from HeyBABE and HeySNAIL cell populations 
and clones were seeded to collagen-coated Transwell inserts and allowed to migrate 
towards 10% FBS for 18 h. Representative images are shown (D) and quantification 
averaged amongst five fields per sample (E). (F, G) Transwell invasion assays using 
fibronectin-coated inserts with representative images (F) and quantification averaged 
amongst five different fields per sample (G). (*, p<0.05 as determined by Student’s t-
test). 
  
98 
 
 
 
Figure 3.10: HeySNAIL spheroid cells have enhanced adhesion. 
(A, B, C) Spheroids formed HeyBABE and HeySNAIL cell populations and clones were 
transferred to standard tissue culture plastic plates (A), fibronectin-coated plates (B), or 
collagen-coated plates (C). Re-attached spheroids were fixed and HEMA3-stained at 30 
min post-reattachment; representative images are shown. 
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Figure 3.11: HeySNAIL spheroid cells have enhanced invasion. 
(A) Spheroids formed from HeyBABE and HeySNAIL cell clones were seeded to 
collagen-coated Transwell inserts and allowed to migrate towards 10% FBS for 18 h. 
Representative images of migrated HEMA3-stained cells are shown. (B) Spheroids 
formed from HeyBABE and HeySNAIL cell clones were seeded to fibronectin-coated 
Transwell inserts and allowed to migrate towards 10% FBS for 18 h. Representative 
images of migrated HEMA3-stained cells are shown. 
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compared with control spheroids (n=52 embryos)(Figure 3.12B and C). Representative 
samples revealed larger, well-defined and apparently more invasive tumour xenografts 
resulting from HeySNAIL spheroids (Figure 3.12B). Fifteen specimens from each group 
were assessed further by histologic analysis. In sections with discernible tumour cells, the 
HeySNAIL group consisted of 8 samples showing cancer cell invasion into the CAM 
stroma and 5 samples with no invasion, where tumour cells remained on the CAM surface.  
In contrast, HeyBABE control spheroids showed only 3 samples with CAM invasion and 
11 with surface tumour cells (data not shown). Human anti-Ki-67 immunostaining 
confirmed presence of xenografted tumour cells, as well as their proliferative potential 
(Figure 3.12D). Since the HeySNAIL spheroid xenografts appeared to have increased 
invasion into the CAM, metastatic capacity was assessed by liver dissection and 
quantitative PCR using isolated genomic DNA from a subset of embryos (n=8 for each 
group).  Using primers for human Alu repeat DNA sequences [18], we observed a trend 
towards greater metastasis to the liver in the HeySNAIL group relative to the HeyBABE 
controls (p=0.052)(Figure 3.12E).  
Taken together, our results strongly suggest that Snail expression in ovarian cancer 
spheroids potentiates adhesion and invasion of these multicellular structures, thereby 
resulting in an enhanced capacity to seed secondary tumour formation. 
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Figure 3.12: HeySNAIL spheroids have enhanced tumour-forming potential in an ex 
vivo chick CAM assay. 
(A) Brightfield and fluorescence microscopy images of day-7 spheroids formed from 
HeyBABE and HeySNAIL cell populations stained with DiO prior to spheroid formation. 
(B) DiO-labelled HeyBABE and HeySNAIL spheroids were inoculated onto the chick 
CAM surface (six spheroids per CAM) and imaged after 7 d incubation. Representative 
brightfield/fluorescence merged images of HeyBABE and HeySNAIL tumours are 
shown. HeySNAIL cells formed much larger tumours. (C) Tumour area was measured 
using ImageJ from six independent experiments (n=48, HeySNAIL; n=52, HeyBABE). 
(***, p<0.001 as determined by Student’s t-test). (D) Representative H&E (left) and 
human anti-Ki-67 immunostaining (brown-stained nuclei; right) for HeyBABE and 
HeySNAIL tumours invading the CAM tissue.  (E) Genomic DNA was extracted from 
the liver of HeyBABE and HeySNAIL groups (n=8 per group) to perform qPCR with 
primers specific for human Alu sequences and normalized to chicken Gapdh. There was a 
strong trend towards higher liver metastasis in the HeySNAIL group compared to 
controls (p=0.0502 as determined by Student’s t-test). 
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3.4 Discussion 
Spheroids serve as the vehicle for dissemination of malignant EOC cells in the 
peritoneal cavity of patients with late-stage disease, protecting cells from anoikis induced 
stress in the extracellular compartment [4, 15]. We have recently observed that epithelial 
ovarian cancer cells induce an endogenous EMT response upon spheroid formation that is 
regulated by endogenous TGFβ signalling and characterized by the robust upregulation of 
Snail in EOC spheroids [10]. Since Snail upregulation is dramatically reduced by TGFβ 
signalling inhibition, herein we sought to investigate the role of Snail in directly mediating 
the malignant potential of EOC spheroids and metastasis of this devastating disease. Via 
SNAI1 knockdown experiments, we show that Snail is required to promote spheroid cell 
migration and for proper cluster formation and spheroid cell viability in a subset of ovarian 
cancer cell lines. Ectopic Snail expression in Hey cells enhanced spheroid cell adhesion, 
invasion and migration potential, which ultimately contributed to increased tumour-
forming and metastatic potential. Snail expression has been observed in primary ovarian 
carcinomas, ovarian cancer effusions and metastases, and associated with shorter overall 
and progression-free survival [27]. Notably, Snail expression has shown to be significantly 
higher in later stage ovarian tumours (III and IV) compared to early-stage ovarian tumours 
[14, 28]. This data clearly implicates Snail in EOC disease progression, and we now 
provide essential insight into its functional role using an experimentally-tractable and 
relevant model of EOC metastasis.  
In epithelial ovarian cancer, the expression of EMT related transcriptional 
repressors along with the loss of E-cadherin has been shown to be related to metastatic and 
recurrent tumour progression. Snail expression in ovarian cancer portends poor patient 
prognosis [29] and platinum resistance [30]. Surprisingly, there are a limited number of 
studies examining Snail function in the progression of EOC. Lu et al. [31] showed that 
SNAI1 overexpression increased cell proliferation, migration, invasion in adherent cell 
culture, while SNAI1 knockdown reduced these effects. SNAI1-overexpressing SKOV3 
cells exhibited higher rates of tumour growth and larger tumour volumes relative to SNAI 
expressing control cells. These effects were not observed by altered SNAI2 (Slug) 
expression, consistent with our previous findings that Slug is not involved in EMT during 
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EOC spheroid formation [10]. SNAI1 silencing in ES-2 and SKOV3 cells resulted in 
decreased MMP-2 and reduces Matrigel invasion in adherent culture [9]. We show that 
SNAI1 knockdown in EOC patient ascites cells severely reduces spheroid cell migration, 
and SNAI1 knockdown in the Ovcar3 and iOvCa147-E2 ovarian cancer cell lines reduces 
spheroid cell viability. Conversely, SNAI1 ectopic expression in Hey cells increases 
anchorage-independent growth, migration, and invasion in 3D spheroid culture assays. 
Given the mode of EOC metastasis, it is particularly relevant to study Snail function in the 
context of spheroids in suspension culture.  
The biological significance and clinical relevance of a 3D cell culture system is 
well-supported in ovarian cancer research, as well as in other cancers. It is important to 
note that our results where we have altered Snail expression in ovarian cancer cells 
substantiate the importance of studying spheroids as compared with adherent, proliferating 
cells. Spheroids more closely mimic the cell-cell, cell-matrix interactions, metabolic 
gradients, cellular viability and differentiation of malignant cells within a solid tumour than 
do conventional adherent, monolayer cultures [32, 33]. As such, recent investigations have 
focused on the invasive properties of ovarian cancer spheroids and their involvement in 
metastatic dissemination. For example, Iwanicki et al. [34] showed that ovarian cancer 
multicellular spheroids attach to monolayer mesothelial cells and promote cell clearance 
by integrin- and force-dependent processes. Expression profiles comparing ovarian cancer 
spheroids that were competent or incompetent to clear mesothelial monolayers yielded 
distinct differences in mesenchymal and epithelial cell marker expression [35]. In fact, 
overexpression of SNAI1, ZEB1, or TWIST1 in clearance-incompetent cell lines 
significantly increased mesothelial clearance ability. Thus, ovarian cancer spheroids 
possessing enhanced mesenchymal characteristics are more efficient at metastasis. Our 
research substantiates these findings since HeySNAIL spheroids have enhanced adhesion, 
migration, and invasion potential both in cell culture- and in vivo-based assays than control 
spheroid cells.  
We found HeySNAIL spheroids had markedly enhanced adhesion to and invasion 
through fibronectin-containing matrices. This may have clinical relevance as several 
isoforms of fibronectin are abundant in the ascites and underlying the mesothelium, which 
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covers the peritoneum and omentum [5, 36].  In other in vitro models of omental metastasis, 
EOC cells have increased ability to adhere to fibronectin matrices [26]. Indeed, ovarian 
cancer cell lines express fibronectin-specific integrin isoforms, which are required for 
efficient EOC cell adhesion [25]. We further investigated spheroid adhesion and invasion 
using an ex ovo chick embryo CAM assay. Snail-expressing spheroids generated larger, 
well-defined, and more invasive tumour xenografts. Surprisingly, we observed a trend 
towards greater liver metastasis by invasive HeySNAIL spheroid xenografts, a result that 
certainly supports the invasion assays performed in cell culture. Of note, a recent study has 
implicated blood-borne metastasis in EOC, a concept that has been largely 
underappreciated in ovarian cancer research [37].  
Taken together, our data strongly suggest that Snail expression in ovarian cancer 
spheroids potentiates adhesion and invasion of these multicellular structures, thereby 
resulting in an enhanced capacity to seed secondary tumour formation. Such results raise 
the possibility that inhibition of Snail could reduce seeding of new ovarian cancer 
metastatic lesions following surgical debulking, thereby minimizing the possibility of 
recurrent metastatic disease. Thus, the findings of our study point out that Snail, and 
perhaps spheroid-induced EMT in general, could represent an attractive and effective target 
in EOC therapeutics.  
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Table S3.1 Clinical data for ovarian cancer patient-derived samples. 
Sample Age Histological Subtype Grade Stage 
EOC82 44 Serous High  IIIC 
EOC138 64 Serous High IIIB 
EOC148 67 Serous High IC 
EOC154 66 Serous High IIIC 
EOC207 65 Serous High n.a. 
EOC237 54 Serous High IIB 
EOC238 70 Serous High  n.a. 
n.a.: not available 
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Chapter 4 
4 DISCUSSION 
4.1 Summary of findings  
Epithelial ovarian cancer is the most lethal gynecologic cancer in the developed 
world. Due to lack of obvious symptoms and effective screening tests, the diagnosis of 
ovarian cancer is often made when the disease is at an advanced stage. At this point, disease 
had spread beyond the primary site, and wide-spread dissemination of cancer cells is found 
within the peritoneal cavity, mainly in the form of spheroids. Despite aggressive surgical 
and chemotherapeutic interventions, most measures are ineffective on these cell structures 
in the peritoneum, which are likely the cause of disease recurrence. As such, mortality rates 
associated with high-grade serous ovarian cancer remain high and have been directly 
attributed to intra-peritoneal/ intra-abdominal metastases. Therefore, experimental models 
that allow us to better comprehend the underlying pathobiology of EOC metastasis are of 
paramount importance to unveil more effective treatment options for patients with late-
stage disease. Our studies specifically use a highly-relevant, tractable, non-adherent culture 
system to examine the molecular underpinnings of multicellular spheroid formation and 
subsequent reattachment to an adherent substratum.  
I specifically focused on the TGFβ signalling pathway and its downstream target 
gene SNAI1/Snail and investigated their roles in spheroid-induced EMT and metastatic 
potential. Using ascites-derived specimens from high-grade serous ovarian cancer patients, 
we observed that epithelial ovarian cancer cells induce an endogenous EMT response upon 
spheroid formation (Chapter 2). I also observed the plasticity of this process, since the cells 
undergo MET to revert back to an epithelial phenotype upon spheroid reattachment to a 
substratum. Importantly, I identified that intact TGFβ signalling is required to elicit this 
EMT response in spheroids since the potent small molecule inhibitor of the TGFβ type I 
receptor, SB-431542, blocks spheroid-induced EMT. Additionally, SB-431542 treatment 
upon spheroid re-attachment forces a more potent epithelial phenotype of dispersing cells, 
thereby decreasing spheroid cell motility and migration. In fact, I found spheroid formation 
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to be significantly compromised by exposure to SB-431542, and this correlated with a 
reduction in cell viability, particularly in combination with carboplatin treatment.  
Since Snail was observed to be the most robustly-upregulated EMT marker 
naturally induced upon EOC spheroid formation, and severely reduced by SB-431542, my 
next objective was to investigate the role of Snail in directly mediating the malignant 
potential of EOC spheroids (Chapter 3). The functional role of Snail in EOC metastasis, 
particularly in spheroids, is largely unknown.  Via SNAI1 knockdown experiments, I show 
that Snail is required to promote spheroid cell migration and for proper cluster formation 
and spheroid cell viability in a subset of ovarian cancer cell lines. We also retrovirally-
transduced the Hey ovarian cancer cell line to ectopically express Snail.  HeySNAIL cells 
exhibited a strong EMT phenotype in adherent culture, a result which correlated with 
significantly enhanced spheroid cell migration, adhesion and invasion to fibronectin and 
collagen matrices. Further to this, using an ex ovo chick embryo chorioallantoic membrane 
assay, Snail-expressing EOC spheroids possessed significantly enhanced tumour-forming 
potential, invasion, and liver metastasis. This data clearly implicates Snail, a direct target 
gene of TGFβ signalling and a master regulator of EMT, in EOC disease progression.  
4.2 The unique and inherent epithelial/mesenchymal plasticity of EOC cells 
uncovered  
Epithelial-to-mesenchymal transition is a universally accepted phenomenon that 
occurs in the malignant progression of most if not all human carcinomas [1]. Dynamics of 
EMT during EOC metastasis, particularly with its reversal, or MET, upon secondary 
tumour formation, has been discussed in the literature [2, 3]. Although EMT has been 
implicated in disease progression, the majority of investigations have studied the 
expression of EMT markers and their related transcription factors in stable cell lines, which 
are induced to undergo EMT either by forced expression of selected transcription factors 
or after prolonged exposure to cytokines such as TGFβ [1, 4, 5]. So far, very limited 
analysis has been performed in fresh cultures directly from patient specimens. Moreover, 
most studies have focused on studying the phenomenon of EMT in 2D cell culture systems, 
which do not properly recapitulate the in vivo tumour microenvironment. In contrast, my 
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studies focused on investigating the expression of EMT-related markers in adherent and 
spheroid cell cultures derived from malignant ascites cells of patients afflicted with high-
grade serous EOC. We employed a biologically-relevant, tractable in vitro model system 
that takes into account the unique mode of ovarian cancer metastasis, whereby multicellular 
spheroids represent an important conduit through which cells are able to survive until they 
reach a mesothelial surface where re-implantation and invasion are possible.  Using this 
model, my studies revealed that ovarian cancer cells within multicellular aggregates or 
spheroids naturally undergo an EMT response, acquiring more mesenchymal 
characteristics, which likely prepares these structures to reattach onto substratum. 
CDH1/E-cadherin expression was markedly reduced in spheroids compared with 
adherent cells, in concert with a robust up-regulation of several transcriptional repressors, 
particularly SNAI1/Snail, as well as TWIST1/2, and ZEB2. In fact, we observed EOC 
spheroids to naturally undergo the reverse, MET, during reattachment and dispersion onto 
substratum. Reversed expression changes of the transcriptional repressors were rapid and 
sustained, although the levels of E-cadherin expression upon spheroid re-attachment did 
not increase to initial levels completely. In fact, E-cadherin expression of ovarian 
carcinoma cells floating in ascites and at metastatic sites has been found to be lower than 
in the primary ovarian tumour [6]. This delay towards a complete MET may perhaps 
facilitate spheroid cell motility and invasion in the very initial phases of spheroid re-
attachment to substratum. In fact, Kumar et al. demonstrated that 3D spheroid cultures 
formed from lung cancer A549 cells show higher migration rates than 2D monolayer 
cultures in an in vitro Transwell assay [7].   
It was interesting to us that an EMT response would be induced in EOC spheroids 
since these cells would not necessarily require a mesenchymal phenotype in these fairly 
static structures. However, one could envision that an EMT phenotype of spheroids primes 
the resident cells for invasive capabilities upon their subsequent reattachment. Indeed, 
evidence from the Brugge lab has demonstrated, in a subset of ovarian cancer cell lines, 
that  ovarian cancer spheroids use myosin-generated force in order to displace the 
mesothelial layer of cells and gain access to the underlying ECM and promote invasion [8]. 
In a subsequent study, they correlated such findings with the expression of mesenchymal 
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and epithelial markers as they demonstrated tumour cells expressing genes associated with 
a mesenchymal program display more effective mesothelial clearance [9]. Furthermore, 
endogenous induction of EMT during cell aggregation into spheroid structures may 
actually be a mechanism EOC cells employ in order to avoid cell death in suspension. In 
fact, it has been reported in the literature that the sensitivity of cells to undergo anoikis can 
be placed along a continuum with epithelial cells being the most susceptible and ﬁbroblasts, 
or mesenchymal-like cells, being the least [10]. Indeed, when we blocked the endogenous 
induction of EMT in our system (via TGFβ signalling inhibition), EOC cells failed to form 
compact spheroids. These less cohesive aggregates further correlated with a reduction in 
cell viability. Others have investigated the expression of EMT-related markers in adherent 
and spheroid cell cultures derived from malignant pleural effusions of patients affected by 
lung adenocarcinoma. In comparing EMT marker expression levels in adherent versus 
spheroid cells, they observed an extremely variable pattern of mesenchymal gene 
expression from sample to sample; however, the one sample that did present typical 
features of EMT (upregulation of Snail, Slug, and Twist) gave rise to the most compact, 
large, and structured spheres [11]. This suggests that EMT may be an important property 
for proper cell aggregation and spheroid formation.  
We observed a very consistent and robust upregulation of SNAI1/Snail upon 
spheroid formation in every single ascites-derived EOC specimen tested, however this was 
not the case for the closely related transcription factor SNAI2/Slug. Although Snail and 
Slug transcription factors share a high degree of homology, and both have been alluded to 
as ”functionally equivalent” in terms of EMT inducers and E-cadherin repressors [12-14], 
significant differences have been observed in their in vitro binding affinities to the E-box 
elements in the promoters of their target genes. When compared, Snail binds to these 
sequences with a higher affinity than Slug and is a more potent inhibitor of CDH1 and 
other target genes (PTEN/PTEN, MUC1/Mucin1, CLDN/Claudin, and OCLN/Occludin) 
[15]. The biological difference between both factors is also highlighted by the distinct 
effect of genetic deletion of SNAI1 or SNAI2 genes in embryonic development: SNAI1 
knockout mice are embryonic lethal [16] while SNAI2 knockout mice are viable [17]. 
Furthermore, functional knockdown studies revealed a specific role for Snail and Slug in 
the tumourigenic and metastatic behavior of squamous carcinoma cells [18]. A distinct role 
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for both factors has also become apparent in other carcinomas, including EOC [19-24], 
which supports our findings that SNAI2/Slug expression is not consistently altered during 
spheroid formation and reattachment. 
 Several groups have also reported that other mesenchymal markers such as 
vimentin and N-cadherin (typically replacing E-cadherin) are commonly induced during 
“classical EMT” in carcinomas [25-29]. We did not observe such occurrences in our model 
system. In fact, the extent of cellular and molecular changes that occur along the pathway 
towards EMT depends on both the cell type and the number of acquired oncogenic 
mutations. Some epithelial cells undergo only a limited amount of change towards EMT. 
Even during developmental EMT, the direct and full conversion from an epithelial to a 
mesenchymal state is not observed in all species [30]. Nevertheless, even small alterations 
in migration and cellular plasticity can impact invasion and metastasis significantly [31]. 
In certain model systems, epithelial cells can undergo a complete loss of expression of all 
epithelial molecular markers accompanied by acquisition of a completely fibroblastoid 
phenotype. This is specifically true in the mouse skin model of chemically-induced 
carcinoma, where the spindle phenotype is driven by TGFβ, but dependent on synergy with 
activation of the oncogenic H-ras signalling pathway [32, 33]. We did not observe such an 
overt EMT in our studies. Taken together, the ability of EOC cells to transition into 
mesenchymal cells and back, either partially or fully, illustrates an inherent plasticity of 
ovarian carcinoma cells. It may be that this dynamic plasticity is a particularly unique and 
advantageous characteristic of metastatic ovarian cancer, not unlike its almost exclusive 
mode of intraperitoneal spread which is unique when compared among other carcinomas. 
4.3 Endogenous TGFβ signalling regulates spheroid-induced EMT 
To assess the mechanism by which spheroid-induced EMT occurs, I focused on 
investigating the role of the TGFβ signalling pathway, not only because it’s the prototypical 
inducer of EMT [34], but also because we have previously observed increased TGFβ1 
expression in EOC ascites-derived spheroids compared to adherent cells [35]. Indeed, 
inhibiting TGFβ signalling during EOC spheroid formation using a potent TβRI small 
molecule inhibitor, SB-431542, efficiently blocked the EMT phenotype in spheroids, 
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rendering these structures much less cohesive and more vulnerable to cell death, 
specifically in combination with carboplatin treatment. Moreover, treating EOC spheroids 
with SB-431542 at the time of reattachment not only dissolved spheroid cell cores, but also 
enhanced the epithelial phenotype of dispersing cells and severely affected their motility 
and migration capacity. It has been suggested in the literature that cells with a higher 
propensity for cell aggregation and compact spheroid formation also have an enhanced 
invasive capacity within 3D matrices [36].  TGFβ treatment of ovarian cancer cell lines 
and breast MCF10A1 cells (and its malignant derivatives) has shown to improve cell 
aggregation and invasion, respectively, in a 3D context [36, 37]. In the 3D breast cancer 
model system, expression of Smad3/4 and MMP2/MMP9 was found to be important in 
TGFβ-induced spheroid cell invasion [38]. Furthermore, in the IGROV1 ovarian cancer 
cell line, treatment of cells with TGFβ1 was shown to increase size and number of 
spheroids, as well as induce expression of stem-like markers [39].  
Results of my studies are the first to show that active maintenance of endogenous 
TGFβ signalling is required to promote the EMT phenotype in EOC spheroids and their 
potential to re-attach and spread. My data also suggests that TGFβ signalling plays a critical 
role in maintaining cell viability and achieving chemo-resistance in ascites-derived EOC 
spheroids. As such, TGFβ signalling may be essential to promote late-stage ovarian cancer 
progression, thus serving as a potential therapeutic target to reduce intraperitoneal spread 
and disease burden upon recurrence.  
In fact, small-molecule inhibitors targeted against TGFβ receptors have been 
effective in different types of cancer in preclinical trials [31]. For example, efﬁcacy of 
TGFβ receptor kinase inhibitors, such as A-77, Ki26894 and LY2109761 was 
demonstrated in preclinical studies of gastric cancer, breast cancer and pancreatic cancer 
[40-42]. A study performed by Sheen et al. showed that EW-7203 (a TβRI inhibitor) had 
suppressive effects on mammary cancer metastasis to the lung using a Balb/c xenograft 
model system. EW-7203 was shown to efficiently inhibit TGFβ-induced Smad signalling 
and EMT in vitro and in vivo [43].  Ge and colleagues published similar results for a 
different TβRI kinase inhibitor, SD-093 [44]. Other examples of small molecules that block 
the catalytic activity of TβRI (SB-431542, SD-208 and SM16) have been reported to be 
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potent antitumour or antimetastatic agents [45-47]. Therefore, in future studies, it would 
be intriguing to test the numerous other TGFβ signalling inhibitors available [48], and 
apply them in an in vivo intraperitoneal ovarian cancer metastasis model. 
4.4 The induced expression of SNAI1/Snail in EOC spheroids acts to facilitate 
disease progression 
Because the underlying pathobiology of EOC spheroid cells was dramatically 
altered by inhibiting the TGFβ signalling pathway, I was curious to investigate which 
downstream target genes are necessary for the metastatic characteristics of ovarian cancer 
spheroids that we’ve observed. Since Snail was consistently and most robustly induced 
upon EOC spheroid cell formation, and severely reduced by SB-431542, I sought to 
investigate its role in EOC progression. Expression of Snail was knocked down using 
siSNAI1, in both ovarian cancer cell lines and EOC ascites-derived cells, using our 
experimentally tractable in vitro model system. Snail was shown to be required for proper 
cluster formation and spheroid cell viability in a subset of ovarian cancer cell lines. 
Although knockdown of SNAI1 led to a modest reduction in spheroid formation and cell 
viability in ascites-derived cells, we observed a severe reduction in the ability of spheroids 
to migrate due to loss of Snail expression. Furthermore, SNAI1 ectopic expression in Hey 
cells (we denoted as ‘HeySNAIL’ cells) showed no differences in cell viability when 
compared to control Hey cells, but displayed enhanced adhesion, migration, and invasion 
potential across different ECM matrices in our 3D spheroid culture assays. This was in 
contrast to the lack of motility differences seen in 2D scratch wound assays, again 
emphasizing the importance of using 3D cell culture systems that better mimic 
physiological features found in solid tumours [49]. Thus, Snail is crucial for the full 
migratory and invasive properties of these multicellular aggregates.  
To assess whether ectopic Snail expression in Hey spheroid cells would enhance 
their ability to attach and form secondary tumours, akin to ovarian cancer trans-coelomic 
metastasis mechanisms, I used an ex ovo chick embryo chorioallantoic membrane (CAM) 
assay. Using the ex ovo chick CAM as a xenograft model facilitates the rapid and direct 
visualization of tumour growth over a duration of only 7 days [50, 51]. Using this model, 
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Snail-expressing spheroids generated larger, well-defined, and more invasive tumour 
xenografts than control Hey spheroids. We also observed a trend towards greater liver 
metastasis by invasive HeySNAIL spheroid xenografts, a result that certainly supports the 
results from our invasion assays performed in cell culture. Taken together, our results 
strongly suggest that Snail expression in ovarian cancer spheroids potentiates adhesion and 
invasion of these multicellular structures, thereby resulting in an enhanced capacity to seed 
secondary tumour formation. 
To complement these studies in the future, we wish to perform similar chick CAM 
assays in high expressing Snail cell lines where SNAI1 would be silenced. We have used 
an RNAi-mediated knockdown approach to target SNAI1 in EOC cells and cell lines in our 
in vitro cell culture assays. This method is commonly used because it’s rapid and 
inexpensive, however knockdown may be incomplete and its inhibition is temporary [52]. 
Recently, the CRISPR/Cas9 (clustered Regularly Interspaced Short Palindromic Repeats/ 
CRISPR-associated 9) system has been developed to enable the precise editing of specific 
genomic loci and facilitate the elucidation of target gene function [53]. Briefly, CRISPR 
“spacer” sequences are transcribed into short RNA sequences capable of guiding the 
system to matching sequences of DNA. When the target DNA is found, Cas9, one of the 
enzymes produced by the CRISPR system, binds to the DNA and cuts it. In the absence of 
a repair template, small insertion or deletion mutations known as indels are formed, leading 
to potential frameshift and truncating mutations, thus shutting off  targeted gene expression 
[54]. Using modified versions of Cas9 and other CRISPR enzymes, this technique has 
shown to be a very efficient tool to permanently modify gene expression [55]. In fact, a 
recent study has used this system to successfully target SNAI1 in serous RMG-1 ovarian 
cancer cells [56]. It would be interesting to apply this into a mouse model of intraperitoneal 
metastasis, and assess ascites generation. Ascites would be harvested from these animals, 
and effect of SNAI1 knockout on spheroid formation potential assessed. The cavities of 
these mice could further be examined to directly assess the ability of spheroids to colonize 
and invade surfaces. As such, effects of silencing SNAI1 on spheroid formation, tumour 
progression, and metastasis could be directly observed in an in vivo setting, to further 
complement our discoveries in a field where the functional role of Snail on the underlying 
pathobiology of EOC spheroids has not been explored. 
119 
 
To summarize, targeting Snail alone did not fully recapitulate the SB-431542 
effects observed on EOC spheroids, indicating that Snail is not the sole mediator of the 
intrinsic TGFβ-induced EMT we observed in EOC spheroids. In other words, targeting 
Snail alone in vitro may not be entirely successful in blocking all of the EMT properties 
that we observed in EOC spheroids, and this is likely due to the presence of multiple factors 
that function together to reinforce the phenotype observed in EOC spheroids. Regardless, 
my studies demonstrate that Snail is important for the adhesive, migratory and invasive 
properties of EOC spheroids, and their resultant capacity to seed secondary tumours. 
Therefore, targeting Snail, or the upstream TGFβ signalling pathway that regulates EMT 
and Snail in spheroids, in late stage ovarian cancer patients is an attractive therapy that 
could minimize the possibility of recurrent metastatic disease.  
4.5 Conclusion  
Epithelial ovarian cancer has one of the poorest prognoses among human 
neoplasms. The goal of this thesis was to contribute to our knowledge of EOC metastasis, 
particularly focusing on multicellular spheroids as major contributors to formation of 
secondary metastatic lesions.  
It has been proposed that cancer cells hijack EMT transcriptional programs to 
dissociate from the primary tumour, intravasate and extravasate through the vasculature, 
and invade distant sites [1, 57-59]. Ovarian cancer cells do not face these barriers in 
metastasizing to the peritoneum. Instead, they are displaced from primary tumours directly 
into the peritoneal cavity, in which single cells aggregate into clusters and acquire survival 
mechanisms that allow them to transit to other peritoneal tissues and colonize new sites. 
We have discovered that EMT is naturally induced upon EOC cell aggregation into 
spheroid structures, a phenomenon that is critical for their survival and malignant behavior. 
We further found that endogenous signalling by the TGFβ signalling pathway regulates 
this spheroid-induced EMT, and its downstream target Snail is crucial for the malignant 
properties that mediate spheroid cell invasion, spread, and secondary tumour formation. 
Understanding the unique characteristics afforded to non-adherent ovarian cancer cells is 
critical for the identification of more effective treatment regimens particularly for late-stage 
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recurrent disease. Overall, this body of work has contributed to the field of ovarian cancer 
metastasis providing rationale for investigating the TGFβ/EMT/Snail pathway further in 
preclinical models. 
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